

10/091,607

L14 63 S L11 AND L12  
L15 6527 S ERYTHROMYCIN  
L16 52 S L14 AND L15  
L17 0 S L16 NOT L15  
L18 9 S LL16 NOT L14  
L19 230 S ACNE/TI  
L20 121 S L19 AND L2  
L21 5 S L20 AND L3  
L22 0 S L21 NOT L15  
L23 5 S L21 AND L15  
L24 1 S L23 AND RADICAL?

=> s skin/ti

L25 4183 SKIN/TI

=> s l25 and l2

L26 542 L25 AND L2

=> s l26 and l3

L27 3 L26 AND L3

=> s l27 and l15

L28 3 L27 AND L15 .

=> s tertiary amine?

128001 TERTIARY

253053 AMINE?

L29 60027 TERTIARY AMINE?  
(TERTIARY(W)AMINE?)

=> s l29 and l28

L30 0 L29 AND L28

=> s l25 and l29

L31 181 L25 AND L29

=> d his

(FILE 'HOME' ENTERED AT 10:41:50 ON 27 JUL 2003)

FILE 'USPATFULL' ENTERED AT 10:42:24 ON 27 JUL 2003

L1 7243 S ACNE?  
L2 118483 S PEROXIDE?  
L3 1027 S DAPSONE?  
L4 2062 S L1 AND L2  
L5 64 S L3 AND L4  
L6 25482 S BENZOYL PEROXIDE?  
L7 34 S L5 AND L6  
L8 41785 S FERROUS OR TRANSITIONAL METAL?  
L9 4 S L7 AND L8  
L10 2524243 S METHOD? OR PROCESS?  
L11 25097 S L10 AND L6  
L12 63 S L3 AND L11  
L13 9188 S ACNE OR SKIN CARE  
L14 63 S L11 AND L12  
L15 6527 S ERYTHROMYCIN  
L16 52 S L14 AND L15  
L17 0 S L16 NOT L15  
L18 9 S LL16 NOT L14  
L19 230 S ACNE/TI  
L20 121 S L19 AND L2  
L21 5 S L20 AND L3

10/091,607

L22 0 S L21 NOT L15  
L23 5 S L21 AND L15  
L24 1 S L23 AND RADICAL?  
L25 4183 S SKIN/TI  
L26 542 S L25 AND L2  
L27 3 S L26 AND L3  
L28 3 S L27 AND L15  
L29 60027 S TERTIARY AMINE?  
L30 0 S L29 AND L28  
L31 181 S L25 AND L29

=> s l31 and l2

L32 63 L31 AND L2

=> s l32 and l3

L33 0 L32 AND L3

=> s l32 and acne

6546 ACNE

L34 27 L32 AND ACNE

=> s l34 and iron?

275146 IRON?

L35 21 L34 AND IRON?

=> s l35 and radical?

206537 RADICAL?

L36 21 L35 AND RADICAL?

=> d his

(FILE 'HOME' ENTERED AT 10:41:50 ON 27 JUL 2003)

FILE 'USPATFULL' ENTERED AT 10:42:24 ON 27 JUL 2003

L1 7243 S ACNE?  
L2 118483 S PEROXIDE?  
L3 1027 S DAPSONE?  
L4 2062 S L1 AND L2  
L5 64 S L3 AND L4  
L6 25482 S BENZOYL PEROXIDE?  
L7 34 S L5 AND L6  
L8 41785 S FERROUS OR TRANSITIONAL METAL?  
L9 4 S L7 AND L8  
L10 2524243 S METHOD? OR PROCESS?  
L11 25097 S L10 AND L6  
L12 63 S L3 AND L11  
L13 9188 S ACNE OR SKIN CARE  
L14 63 S L11 AND L12  
L15 6527 S ERYTHROMYCIN  
L16 52 S L14 AND L15  
L17 0 S L16 NOT L15  
L18 9 S L16 NOT L14  
L19 230 S ACNE/TI  
L20 121 S L19 AND L2  
L21 5 S L20 AND L3  
L22 0 S L21 NOT L15  
L23 5 S L21 AND L15  
L24 1 S L23 AND RADICAL?  
L25 4183 S SKIN/TI  
L26 542 S L25 AND L2  
L27 3 S L26 AND L3  
L28 3 S L27 AND L15

10/091,607

L29 60027 S TERTIARY AMINE?  
L30 0 S L29 AND L28  
L31 181 S L25 AND L29  
L32 63 S L31 AND L2  
L33 0 S L32 AND L3  
L34 27 S L32 AND ACNE  
L35 21 S L34 AND IRON?  
L36 21 S L35 AND RADICAL?

=> s l36 and l6

L37 21 L36 AND L6

=> s l15 and l37

L38 21 L15 AND L37

=>

=> d l28 ibib abs 1-3

L28 ANSWER 1 OF 3 USPATFULL on STN

ACCESSION NUMBER: 90:5872 USPATFULL

TITLE: Pharmaceutical vehicles for enhancing penetration and retention in the **skin**

INVENTOR(S): Allen, Larry M., Denver, CO, United States

PATENT ASSIGNEE(S): Chemex Pharmaceuticals, Inc., Denver, CO, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4895727		19900123
APPLICATION INFO.:	US 1985-730682		19850503 (6)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Maple, John S.		
LEGAL REPRESENTATIVE:	Kenyon & Kenyon		
NUMBER OF CLAIMS:	30		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)		
LINE COUNT:	1116		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention is a method of inducing a reservoir effect in skin and mucous membranes so as to enhance penetration and retention and reduce transdermal flux of topically applied therapeutic and cosmetic pharmacologically active agents. The invention also relates to topical treatment methods involving such reservoir effect enhancers, and to pharmaceutical compositions containing them.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 2 OF 3 USPATFULL on STN

ACCESSION NUMBER: 89:97369 USPATFULL

TITLE: Topical transretinoids for treatment of acne and **skin** diseases

INVENTOR(S): Parish, Harlie A., Memphis, TN, United States

Purcell, William P., Memphis, TN, United States

PATENT ASSIGNEE(S): Molecular Design International, Memphis, TN, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4885311		19891205
APPLICATION INFO.:	US 1987-67536		19870629 (7)
DOCUMENT TYPE:	Utility		

10/091,607

FILE SEGMENT: Granted  
PRIMARY EXAMINER: Lone, Werren B.  
ASSISTANT EXAMINER: Clarke, Vera C.  
LEGAL REPRESENTATIVE: Waldron & Associates  
NUMBER OF CLAIMS: 14  
EXEMPLARY CLAIM: 1,3  
LINE COUNT: 405

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Esters and amides of 13-trans-retinoic acid are disclosed which are used for the treatment of acne and skin diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 3 OF 3 USPATFULL on STN

ACCESSION NUMBER: 87:47047 USPATFULL  
TITLE: Topical prodrugs for treatment of acne and skin diseases  
INVENTOR(S): Parish, Harlie A., Memphis, TN, United States  
Purcell, William P., Memphis, TN, United States  
PATENT ASSIGNEE(S): Molecular Design International, Memphis, TN, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4677120		19870630
APPLICATION INFO.:	US 1985-760881		19850731 (6)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Lone, Werren B.		
ASSISTANT EXAMINER:	Clarke, Vera C.		
LEGAL REPRESENTATIVE:	Waldron, James S.		
NUMBER OF CLAIMS:	14		
EXEMPLARY CLAIM:	1,3		
LINE COUNT:	623		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Esters and amides of 13-cis-retinoic acid are disclosed which are used for the treatment of acne and skin diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 10:41:50 ON 27 JUL 2003)

FILE 'USPATFULL' ENTERED AT 10:42:24 ON 27 JUL 2003

L1 7243 S ACNE?  
L2 118483 S PEROXIDE?  
L3 1027 S DAPSONE?  
L4 2062 S L1 AND L2  
L5 64 S L3 AND L4  
L6 25482 S BENZOYL PEROXIDE?  
L7 34 S L5 AND L6  
L8 41785 S FERROUS OR TRANSITIONAL METAL?  
L9 4 S L7 AND L8  
L10 2524243 S METHOD? OR PROCESS?  
L11 25097 S L10 AND L6  
L12 63 S L3 AND L11  
L13 9188 S ACNE OR SKIN CARE  
L14 63 S L11 AND L12  
L15 6527 S ERYTHROMYCIN  
L16 52 S L14 AND L15

10/091,607

L17 0 S L16 NOT L15  
L18 9 S LL16 NOT L14  
L19 230 S ACNE/TI  
L20 121 S L19 AND L2  
L21 5 S L20 AND L3  
L22 0 S L21 NOT L15  
L23 5 S L21 AND L15  
L24 1 S L23 AND RADICAL?  
L25 4183 S SKIN/TI  
L26 542 S L25 AND L2  
L27 3 S L26 AND L3  
L28 3 S L27 AND L15  
L29 60027 S TERTIARY AMINE?  
L30 0 S L29 AND L28  
L31 181 S L25 AND L29  
L32 63 S L31 AND L2  
L33 0 S L32 AND L3  
L34 27 S L32 AND ACNE  
L35 21 S L34 AND IRON?  
L36 21 S L35 AND RADICAL?  
L37 21 S L36 AND L6  
L38 21 S L15 AND L37

=> d 127 ibib abs 1-3

L27 ANSWER 1 OF 3 USPATFULL on STN

ACCESSION NUMBER: 90:5872 USPATFULL

TITLE: Pharmaceutical vehicles for enhancing penetration and retention in the skin

INVENTOR(S): Allen, Larry M., Denver, CO, United States

PATENT ASSIGNEE(S): Chemex Pharmaceuticals, Inc., Denver, CO, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4895727		19900123
APPLICATION INFO.:	US 1985-730682		19850503 (6)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Maple, John S.		
LEGAL REPRESENTATIVE:	Kenyon & Kenyon		
NUMBER OF CLAIMS:	30		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)		
LINE COUNT:	1116		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention is a method of inducing a reservoir effect in skin and mucous membranes so as to enhance penetration and retention and reduce transdermal flux of topically applied therapeutic and cosmetic pharmacologically active agents. The invention also relates to topical treatment methods involving such reservoir effect enhancers, and to pharmaceutical compositions containing them.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L27 ANSWER 2 OF 3 USPATFULL on STN

ACCESSION NUMBER: 89:97369 USPATFULL

TITLE: Topical transretinoids for treatment of acne and skin diseases

INVENTOR(S): Parish, Harlie A., Memphis, TN, United States

Purcell, William P., Memphis, TN, United States

PATENT ASSIGNEE(S): Molecular Design International, Memphis, TN, United States

10/091,607

States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4885311		19891205
APPLICATION INFO.:	US 1987-67536		19870629 (7)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Lone, Werren B.		
ASSISTANT EXAMINER:	Clarke, Vera C.		
LEGAL REPRESENTATIVE:	Waldron & Associates		
NUMBER OF CLAIMS:	14		
EXEMPLARY CLAIM:	1,3		
LINE COUNT:	405		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Esters and amides of 13-trans-retinoic acid are disclosed which are used for the treatment of acne and skin diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L27 ANSWER 3 OF 3 USPATFULL on STN

ACCESSION NUMBER: 87:47047 USPATFULL

TITLE: Topical prodrugs for treatment of acne and skin diseases

INVENTOR(S): Parish, Harlie A., Memphis, TN, United States  
Purcell, William P., Memphis, TN, United States

PATENT ASSIGNEE(S): Molecular Design International, Memphis, TN, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4677120		19870630
APPLICATION INFO.:	US 1985-760881		19850731 (6)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Lone, Werren B.		
ASSISTANT EXAMINER:	Clarke, Vera C.		
LEGAL REPRESENTATIVE:	Waldron, James S.		
NUMBER OF CLAIMS:	14		
EXEMPLARY CLAIM:	1,3		
LINE COUNT:	623		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Esters and amides of 13-cis-retinoic acid are disclosed which are used for the treatment of acne and skin diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d 123 1-5 ibib abs

L23 ANSWER 1 OF 5 USPATFULL on STN

ACCESSION NUMBER: 2002:332478 USPATFULL

TITLE: Acne patch

INVENTOR(S): Buseman, Teri, Minnetonka, MN, United States  
Rolf, David, Eden Prairie, MN, United States  
McWhorter, Daniel M., Eagan, MN, United States

PATENT ASSIGNEE(S): Lec Tec Corporation, Minnetonka, MN, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6495158	B1	20021217

10/091,607

APPLICATION INFO.: US 2001-766885 20010119 (9)  
DOCUMENT TYPE: Utility  
FILE SEGMENT: GRANTED  
PRIMARY EXAMINER: Dees, Jos' G.  
ASSISTANT EXAMINER: Haghighatian, Mina  
LEGAL REPRESENTATIVE: Schwegman, Lundberg, Woessner & Kluth, P.A.  
NUMBER OF CLAIMS: 77  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 10 Drawing Figure(s); 5 Drawing Page(s)  
LINE COUNT: 1816

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An adhesive patch is provided wherein the patch includes a flexible backing having a front side and a back side. The patch also includes a therapeutic formulation positioned on and in at least a portion of the front side of the backing such that the therapeutic formulation is partially embedded in at least a portion of the front side of the backing. At least a portion of the backing is treated with a hydrophobic sizing agent such that the portion of the backing that is treated with the hydrophobic sizing agent has a surface energy of about 20 dynes/cm.sup.2 to about 65 dynes/cm.sup.2. The therapeutic formulation includes a topical acne drug, a solvent that dissolves the topical acne drug, and a pressure sensitive adhesive.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L23 ANSWER 2 OF 5 USPATFULL on STN

ACCESSION NUMBER: 97:118083 USPATFULL  
TITLE: Method for treating acne  
INVENTOR(S): Peck, Gary L., Silver Spring, MD, United States  
PATENT ASSIGNEE(S): The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5698593		19971216
APPLICATION INFO.:	US 1993-47007		19930415 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1991-735113, filed on 24 Jul 1991, now abandoned which is a continuation of Ser. No. US 1988-186260, filed on 26 Apr 1988, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Weddington, Kevin E.		
LEGAL REPRESENTATIVE:	Hyman, Laurence J. Office of Technology Transfer, NIH		
NUMBER OF CLAIMS:	11		
EXEMPLARY CLAIM:	1		
LINE COUNT:	393		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Nodulocystic and conglobate acne in humans can be alleviated by the oral administration of 13-cis-retinoic acid or a derivative thereof. The active ingredient is administered in a dosage of from about 1.5 to about 3 mg/kg of body weight per day for a period of from about two to about four weeks.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L23 ANSWER 3 OF 5 USPATFULL on STN

ACCESSION NUMBER: 96:70456 USPATFULL  
TITLE: Combination method of treating acne using 4-AZA-5.alpha.-cholestan-ones and 4-AZA-5.alpha.-androstan-ones as selective 5.alpha.-reductase inhibitors with anti-bacterial, keratolytic, or

10/091,607

INVENTOR(S): anti-inflammatory agents  
Waldstreicher, Joanne, Scotch Plains, NJ, United States  
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5543417		19960806
APPLICATION INFO.:	US 1994-327078		19941021 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Killos, Paul J.		
LEGAL REPRESENTATIVE:	Fitch, Catherine D., North, Robert J., Winokur, Melvin		
NUMBER OF CLAIMS:	31		
EXEMPLARY CLAIM:	1		
LINE COUNT:	3981		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Described is a combination method using selective inhibitors of 5.alpha.-reductase 1 and/or 2 including 7.beta.-substituted 4-aza-5.alpha.-cholestan-3-ones and related 4-aza-5.alpha.-androstan-3-one compounds which are useful in the treatment of acne vulgaris in combination with at least one agent selected from an antibacterial, keratolytic, and/or an anti-inflammatory.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L23 ANSWER 4 OF 5 USPATFULL on STN

ACCESSION NUMBER: 89:97369 USPATFULL  
TITLE: Topical transretinoids for treatment of acne and skin diseases  
INVENTOR(S): Parish, Harlie A., Memphis, TN, United States  
Purcell, William P., Memphis, TN, United States  
PATENT ASSIGNEE(S): Molecular Design International, Memphis, TN, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4885311		19891205
APPLICATION INFO.:	US 1987-67536		19870629 (7)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Lone, Werren B.		
ASSISTANT EXAMINER:	Clarke, Vera C.		
LEGAL REPRESENTATIVE:	Waldron & Associates		
NUMBER OF CLAIMS:	14		
EXEMPLARY CLAIM:	1,3		
LINE COUNT:	405		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Esters and amides of 13-trans-retinoic acid are disclosed which are used for the treatment of acne and skin diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L23 ANSWER 5 OF 5 USPATFULL on STN

ACCESSION NUMBER: 87:47047 USPATFULL  
TITLE: Topical prodrugs for treatment of acne and skin diseases  
INVENTOR(S): Parish, Harlie A., Memphis, TN, United States  
Purcell, William P., Memphis, TN, United States  
PATENT ASSIGNEE(S): Molecular Design International, Memphis, TN, United States (U.S. corporation)



10/091,607

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4677120		19870630
APPLICATION INFO.:	US 1985-760881		19850731 (6)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Lone, Werren B.		
ASSISTANT EXAMINER:	Clarke, Vera C.		
LEGAL REPRESENTATIVE:	Waldron, James S.		
NUMBER OF CLAIMS:	14		
EXEMPLARY CLAIM:	1,3		
LINE COUNT:	623		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Esters and amides of 13-cis-retinoic acid are disclosed which are used for the treatment of acne and skin diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s d his

1465381 D

270752 HIS

L39 562 D HIS

(D(W)HIS)

=> d his

(FILE 'HOME' ENTERED AT 10:41:50 ON 27 JUL 2003)

FILE 'USPATFULL' ENTERED AT 10:42:24 ON 27 JUL 2003

L1 7243 S ACNE?  
L2 118483 S PEROXIDE?  
L3 1027 S DAPSONE?  
L4 2062 S L1 AND L2  
L5 64 S L3 AND L4  
L6 25482 S BENZOYL PEROXIDE?  
L7 34 S L5 AND L6  
L8 41785 S FERROUS OR TRANSITIONAL METAL?  
L9 4 S L7 AND L8  
L10 2524243 S METHOD? OR PROCESS?  
L11 25097 S L10 AND L6  
L12 63 S L3 AND L11  
L13 9188 S ACNE OR SKIN CARE  
L14 63 S L11 AND L12  
L15 6527 S ERYTHROMYCIN  
L16 52 S L14 AND L15  
L17 0 S L16 NOT L15  
L18 9 S LL16 NOT L14  
L19 230 S ACNE/TI  
L20 121 S L19 AND L2  
L21 5 S L20 AND L3  
L22 0 S L21 NOT L15  
L23 5 S L21 AND L15  
L24 1 S L23 AND RADICAL?  
L25 4183 S SKIN/TI  
L26 542 S L25 AND L2  
L27 3 S L26 AND L3  
L28 3 S L27 AND L15  
L29 60027 S TERTIARY AMINE?  
L30 0 S L29 AND L28  
L31 181 S L25 AND L29  
L32 63 S L31 AND L2

10/091,607

L33	0 S L32 AND L3
L34	27 S L32 AND ACNE
L35	21 S L34 AND IRON?
L36	21 S L35 AND RADICAL?
L37	21 S L36 AND L6
L38	21 S L15 AND L37
L39	562 S D HIS

10/091,607

=> s acne/ti or skin care/ti

230 ACNE/TI  
4183 SKIN/TI  
1843 CARE/TI  
248 SKIN CARE/TI  
((SKIN(W)CARE)/TI)  
L40 478 ACNE/TI OR SKIN CARE/TI

=> d his

(FILE 'HOME' ENTERED AT 10:41:50 ON 27 JUL 2003)

FILE 'USPATFULL' ENTERED AT 10:42:24 ON 27 JUL 2003

L1 7243 S ACNE?  
L2 118483 S PEROXIDE?  
L3 1027 S DAPSONE?  
L4 2062 S L1 AND L2  
L5 64 S L3 AND L4  
L6 25482 S BENZOYL PEROXIDE?  
L7 34 S L5 AND L6  
L8 41785 S FERROUS OR TRANSITIONAL METAL?  
L9 4 S L7 AND L8  
L10 2524243 S METHOD? OR PROCESS?  
L11 25097 S L10 AND L6  
L12 63 S L3 AND L11  
L13 9188 S ACNE OR SKIN CARE  
L14 63 S L11 AND L12  
L15 6527 S ERYTHROMYCIN  
L16 52 S L14 AND L15  
L17 0 S L16 NOT L15  
L18 9 S LL16 NOT L14  
L19 230 S ACNE/TI  
L20 121 S L19 AND L2  
L21 5 S L20 AND L3  
L22 0 S L21 NOT L15  
L23 5 S L21 AND L15  
L24 1 S L23 AND RADICAL?  
L25 4183 S SKIN/TI  
L26 542 S L25 AND L2  
L27 3 S L26 AND L3  
L28 3 S L27 AND L15  
L29 60027 S TERTIARY AMINE?  
L30 0 S L29 AND L28  
L31 181 S L25 AND L29  
L32 63 S L31 AND L2  
L33 0 S L32 AND L3  
L34 27 S L32 AND ACNE  
L35 21 S L34 AND IRON?  
L36 21 S L35 AND RADICAL?  
L37 21 S L36 AND L6  
L38 21 S L15 AND L37  
L39 562 S D HIS  
L40 478 S ACNE/TI OR SKIN CARE/TI

10/091,607

=> s acne/ti or skin care/ti

230 ACNE/TI  
4183 SKIN/TI  
1843 CARE/TI  
248 SKIN CARE/TI  
((SKIN(W)CARE)/TI)  
L40 478 ACNE/TI OR SKIN CARE/TI

=> d his

(FILE 'HOME' ENTERED AT 10:41:50 ON 27 JUL 2003)

FILE 'USPATFULL' ENTERED AT 10:42:24 ON 27 JUL 2003

L1 7243 S ACNE?  
L2 118483 S PEROXIDE?  
L3 1027 S DAPSONE?  
L4 2062 S L1 AND L2  
L5 64 S L3 AND L4  
L6 25482 S BENZOYL PEROXIDE?  
L7 34 S L5 AND L6  
L8 41785 S FERROUS OR TRANSITIONAL METAL?  
L9 4 S L7 AND L8  
L10 2524243 S METHOD? OR PROCESS?  
L11 25097 S L10 AND L6  
L12 63 S L3 AND L11  
L13 9188 S ACNE OR SKIN CARE  
L14 63 S L11 AND L12  
L15 6527 S ERYTHROMYCIN  
L16 52 S L14 AND L15  
L17 0 S L16 NOT L15  
L18 9 S LL16 NOT L14  
L19 230 S ACNE/TI  
L20 121 S L19 AND L2  
L21 5 S L20 AND L3  
L22 0 S L21 NOT L15  
L23 5 S L21 AND L15  
L24 1 S L23 AND RADICAL?  
L25 4183 S SKIN/TI  
L26 542 S L25 AND L2  
L27 3 S L26 AND L3  
L28 3 S L27 AND L15  
L29 60027 S TERTIARY AMINE?  
L30 0 S L29 AND L28  
L31 181 S L25 AND L29  
L32 63 S L31 AND L2  
L33 0 S L32 AND L3  
L34 27 S L32 AND ACNE  
L35 21 S L34 AND IRON?  
L36 21 S L35 AND RADICAL?  
L37 21 S L36 AND L6  
L38 21 S L15 AND L37  
L39 562 S D HIS  
L40 478 S ACNE/TI OR SKIN CARE/TI

10/091,607

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal503sxd

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	Feb 24	PCTGEN now available on STN
NEWS	4	Feb 24	TEMA now available on STN
NEWS	5	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS	6	Feb 26	PCTFULL now contains images
NEWS	7	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS	8	Mar 24	PATDPAFULL now available on STN
NEWS	9	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS	10	Apr 11	Display formats in DGENE enhanced
NEWS	11	Apr 14	MEDLINE Reload
NEWS	12	Apr 17	Polymer searching in REGISTRY enhanced
NEWS	13	Jun 13	Indexing from 1947 to 1956 added to records in CA/CAPLUS
NEWS	14	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS	15	Apr 28	RDISCLOSURE now available on STN
NEWS	16	May 05	Pharmacokinetic information and systematic chemical names added to PHAR
NEWS	17	May 15	MEDLINE file segment of TOXCENTER reloaded
NEWS	18	May 15	Supporter information for ENCOMPAT and ENCOMPLIT updated
NEWS	19	May 19	Simultaneous left and right truncation added to WSCA
NEWS	20	May 19	RAPRA enhanced with new search field, simultaneous left and right truncation
NEWS	21	Jun 06	Simultaneous left and right truncation added to CBNB
NEWS	22	Jun 06	PASCAL enhanced with additional data
NEWS	23	Jun 20	2003 edition of the FSTA Thesaurus is now available
NEWS	24	Jun 25	HSDB has been reloaded
NEWS	25	Jul 16	Data from 1960-1976 added to RDISCLOSURE
NEWS	26	Jul 21	Identification of STN records implemented
NEWS	27	Jul 21	Polymer class term count added to REGISTRY
NEWS	28	Jul 22	INPADOC: Basic index (/BI) enhanced; Simultaneous Left and Right Truncation available
NEWS EXPRESS			April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

10/091,607

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 10:41:50 ON 27 JUL 2003

=> file uspatfull  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'USPATFULL' ENTERED AT 10:42:24 ON 27 JUL 2003  
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 24 Jul 2003 (20030724/PD)  
FILE LAST UPDATED: 24 Jul 2003 (20030724/ED)  
HIGHEST GRANTED PATENT NUMBER: US6598233  
HIGHEST APPLICATION PUBLICATION NUMBER: US2003140390  
CA INDEXING IS CURRENT THROUGH 24 Jul 2003 (20030724/UPCA)  
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 24 Jul 2003 (20030724/PD)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2003  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2003

>>> USPAT2 is now available. USPATFULL contains full text of the <<<  
>>> original, i.e., the earliest published granted patents or <<<  
>>> applications. USPAT2 contains full text of the latest US <<<  
>>> publications, starting in 2001, for the inventions covered in <<<  
>>> USPATFULL. A USPATFULL record contains not only the original <<<  
>>> published document but also a list of any subsequent <<<  
>>> publications. The publication number, patent kind code, and <<<  
>>> publication date for all the US publications for an invention <<<  
>>> are displayed in the PI (Patent Information) field of USPATFULL <<<  
>>> records and may be searched in standard search fields, e.g., /PN, <<<  
>>> /PK, etc. <<<

>>> USPATFULL and USPAT2 can be accessed and searched together <<<  
>>> through the new cluster USPATALL. Type FILE USPATALL to <<<  
>>> enter this cluster. <<<  
>>> <<<  
>>> Use USPATALL when searching terms such as patent assignees, <<<  
>>> classifications, or claims, that may potentially change from <<<  
>>> the earliest to the latest publication. <<<

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s acne?  
L1 7243 ACNE?

=> s peroxide?  
L2 118483 PEROXIDE?

=> s dapsone?  
L3 1027 DAPSONE?

=> s l1 and l2  
L4 2062 L1 AND L2

10/091,607

NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)

LINE COUNT: 532

AB A static random access memory (SRAM) employs a modified divided word architecture in which each address selects cells from plural blocks. Thus, each word is dispersed among multiple blocks, rather than being confined to a single block as in conventional divided word architectures. More specifically, the blocks are divided among four quadrants of the array and data pads (or ports) are arranged on opposite sides of the array. This architecture causes each word to be divided among all four quadrants. Each quadrant is coupled via a respective data bus to the data ports adjacent to the quadrant. This arrangement reduces data path lengths within the SRAM, improving overall access times.

L18 ANSWER 9 OF 9 USPATFULL on STN

ACCESSION NUMBER: 75:67012 USPATFULL

TITLE: Fabricating apparatus for twin-sheets

INVENTOR(S): Brown, Gaylord W., Beaverton, MI, United States

PATENT ASSIGNEE(S): Koehring Company, Milwaukee, WI, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 3925140		19751209
APPLICATION INFO.:	US 1973-341850		19730316 (5)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Weston, Caleb		
NUMBER OF CLAIMS:	3		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	9 Drawing Figure(s); 8 Drawing Page(s)		
LINE COUNT:	857		

AB Apparatus and methods for fabricating a hollow plastic object from a pair of heat-fusible, thermoplastic sheets which are serially moved in a common horizontal plane from a heating station to a mold mechanism at a forming station. At the forming station, one of the sheets is received by a mold which is then moved vertically to move the sheet out of the plane to a position juxtaposed with a following sheet when the latter arrives at the forming station. At least one of the sheets is differential pressure molded after arrival at the forming station and the sheets are then vertically moved together and fused to form the object.

=>

=> s acne/ti

L19 230 ACNE/TI

=> d his

(FILE 'HOME' ENTERED AT 10:41:50 ON 27 JUL 2003)

FILE 'USPATFULL' ENTERED AT 10:42:24 ON 27 JUL 2003

L1 7243 S ACNE?  
L2 118483 S PEROXIDE?  
L3 1027 S DAPSONE?  
L4 2062 S L1 AND L2  
L5 64 S L3 AND L4  
L6 25482 S BENZOYL PEROXIDE?  
L7 34 S L5 AND L6  
L8 41785 S FERROUS OR TRANSITIONAL METAL?

10/091,607

L9 4 S L7 AND L8  
L10 2524243 S METHOD? OR PROCESS?  
L11 25097 S L10 AND L6  
L12 63 S L3 AND L11  
L13 9188 S ACNE OR SKIN CARE  
L14 63 S L11 AND L12  
L15 6527 S ERYTHROMYCIN  
L16 52 S L14 AND L15  
L17 0 S L16 NOT L15  
L18 9 S L16 NOT L14  
L19 230 S ACNE/TI

=> s l19 and l2  
L20 121 L19 AND L2

=> s l20 and l3  
L21 5 L20 AND L3

=> s l21 not l15  
L22 0 L21 NOT L15

=> s l21 and l15  
L23 5 L21 AND L15

=> d 1-5 ibib abs

L23 ANSWER 1 OF 5 USPATFULL on STN

ACCESSION NUMBER: 2002:332478 USPATFULL

TITLE: Acne patch

INVENTOR(S): Buseman, Teri, Minnetonka, MN, United States  
Rolf, David, Eden Prairie, MN, United States  
McWhorter, Daniel M., Eagan, MN, United States

PATENT ASSIGNEE(S): Lec Tec Corporation, Minnetonka, MN, United States  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6495158	B1	20021217
APPLICATION INFO.:	US 2001-766885		20010119 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Dees, Jos' G.		
ASSISTANT EXAMINER:	Haghighatian, Mina		
LEGAL REPRESENTATIVE:	Schwegman, Lundberg, Woessner & Kluth, P.A.		
NUMBER OF CLAIMS:	77		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	10 Drawing Figure(s); 5 Drawing Page(s)		
LINE COUNT:	1816		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An adhesive patch is provided wherein the patch includes a flexible backing having a front side and a back side. The patch also includes a therapeutic formulation positioned on and in at least a portion of the front side of the backing such that the therapeutic formulation is partially embedded in at least a portion of the front side of the backing. At least a portion of the backing is treated with a hydrophobic sizing agent such that the portion of the backing that is treated with the hydrophobic sizing agent has a surface energy of about 20 dynes/cm.sup.2 to about 65 dynes/cm.sup.2. The therapeutic formulation includes a topical acne drug, a solvent that dissolves the topical acne drug, and a pressure sensitive adhesive.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.



10/091,607

L23 ANSWER 2 OF 5 USPATFULL on STN

ACCESSION NUMBER: 97:118083 USPATFULL  
TITLE: Method for treating **acne**  
INVENTOR(S): Peck, Gary L., Silver Spring, MD, United States  
PATENT ASSIGNEE(S): The United States of America as represented by the  
Department of Health and Human Services, Washington,  
DC, United States (U.S. government)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5698593		19971216
APPLICATION INFO.:	US 1993-47007		19930415 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1991-735113, filed on 24 Jul 1991, now abandoned which is a continuation of Ser. No. US 1988-186260, filed on 26 Apr 1988, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Weddington, Kevin E.		
LEGAL REPRESENTATIVE:	Hyman, Laurence J. Office of Technology Transfer, NIH		
NUMBER OF CLAIMS:	11		
EXEMPLARY CLAIM:	1		
LINE COUNT:	393		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Nodulocystic and conglobate acne in humans can be alleviated by the oral administration of 13-cis-retinoic acid or a derivative thereof. The active ingredient is administered in a dosage of from about 1.5 to about 3 mg/kg of body weight per day for a period of from about two to about four weeks.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L23 ANSWER 3 OF 5 USPATFULL on STN

ACCESSION NUMBER: 96:70456 USPATFULL  
TITLE: Combination method of treating **acne** using  
4-AZA-5.alpha.-cholestan-ones and 4-AZA-5.alpha.-  
androstan-ones as selective 5.alpha.-reductase  
inhibitors with anti-bacterial, keratolytic, or  
anti-inflammatory agents  
INVENTOR(S): Waldstreicher, Joanne, Scotch Plains, NJ, United States  
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5543417		19960806
APPLICATION INFO.:	US 1994-327078		19941021 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Killos, Paul J.		
LEGAL REPRESENTATIVE:	Fitch, Catherine D., North, Robert J., Winokur, Melvin		
NUMBER OF CLAIMS:	31		
EXEMPLARY CLAIM:	1		
LINE COUNT:	3981		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Described is a combination method using selective inhibitors of 5.alpha.-reductase 1 and/or 2 including 7.beta.-substituted 4-aza-5.alpha.-cholestan-3-ones and related 4-aza-5.alpha.-androstan-3-one compounds which are useful in the treatment of acne vulgaris in combination with at least one agent selected from an antibacterial, keratolytic, and/or an anti-inflammatory.

10/091,607

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L23 ANSWER 4 OF 5 USPATFULL on STN

ACCESSION NUMBER: 89:97369 USPATFULL  
TITLE: Topical transretinoids for treatment of **acne**  
and skin diseases  
INVENTOR(S): Parish, Harlie A., Memphis, TN, United States  
Purcell, William P., Memphis, TN, United States  
PATENT ASSIGNEE(S): Molecular Design International, Memphis, TN, United  
States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4885311		19891205
APPLICATION INFO.:	US 1987-67536		19870629 (7)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Lone, Werren B.		
ASSISTANT EXAMINER:	Clarke, Vera C.		
LEGAL REPRESENTATIVE:	Waldron & Associates		
NUMBER OF CLAIMS:	14		
EXEMPLARY CLAIM:	1,3		
LINE COUNT:	405		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Esters and amides of 13-trans-retinoic acid are disclosed which are used  
for the treatment of acne and skin diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L23 ANSWER 5 OF 5 USPATFULL on STN

ACCESSION NUMBER: 87:47047 USPATFULL  
TITLE: Topical prodrugs for treatment of **acne** and  
skin diseases  
INVENTOR(S): Parish, Harlie A., Memphis, TN, United States  
Purcell, William P., Memphis, TN, United States  
PATENT ASSIGNEE(S): Molecular Design International, Memphis, TN, United  
States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4677120		19870630
APPLICATION INFO.:	US 1985-760881		19850731 (6)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Lone, Werren B.		
ASSISTANT EXAMINER:	Clarke, Vera C.		
LEGAL REPRESENTATIVE:	Waldron, James S.		
NUMBER OF CLAIMS:	14		
EXEMPLARY CLAIM:	1,3		
LINE COUNT:	623		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Esters and amides of 13-cis-retinoic acid are disclosed which are used  
for the treatment of acne and skin diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 10:41:50 ON 27 JUL 2003)

FILE 'USPATFULL' ENTERED AT 10:42:24 ON 27 JUL 2003

10/091,607

L1 7243 S ACNE?  
L2 118483 S PEROXIDE?  
L3 1027 S DAPSONE?  
L4 2062 S L1 AND L2  
L5 64 S L3 AND L4  
L6 25482 S BENZOYL PEROXIDE?  
L7 34 S L5 AND L6  
L8 41785 S FERROUS OR TRANSITIONAL METAL?  
L9 4 S L7 AND L8  
L10 2524243 S METHOD? OR PROCESS?  
L11 25097 S L10 AND L6  
L12 63 S L3 AND L11  
L13 9188 S ACNE OR SKIN CARE  
L14 63 S L11 AND L12  
L15 6527 S ERYTHROMYCIN  
L16 52 S L14 AND L15  
L17 0 S L16 NOT L15  
L18 9 S L16 NOT L14  
L19 230 S ACNE/TI  
L20 121 S L19 AND L2  
L21 5 S L20 AND L3  
L22 0 S L21 NOT L15  
L23 5 S L21 AND L15

=> s l23 and radical?

206537 RADICAL?

L24 1 L23 AND RADICAL?

=> d 1 ibib abs

L24 ANSWER 1 OF 1 USPATFULL on STN

ACCESSION NUMBER: 96:70456 USPATFULL

TITLE: Combination method of treating acne using  
4-AZA-5.alpha.-cholestan-ones and 4-AZA-5.alpha.-  
androstan-ones as selective 5.alpha.-reductase  
inhibitors with anti-bacterial, keratolytic, or  
anti-inflammatory agents

INVENTOR(S): Waldstreicher, Joanne, Scotch Plains, NJ, United States

PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5543417		19960806
APPLICATION INFO.:	US 1994-327078		19941021 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Killos, Paul J.		
LEGAL REPRESENTATIVE:	Fitch, Catherine D., North, Robert J., Winokur, Melvin		
NUMBER OF CLAIMS:	31		
EXEMPLARY CLAIM:	1		
LINE COUNT:	3981		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Described is a combination method using selective inhibitors of  
5.alpha.-reductase 1 and/or 2 including 7.beta.-substituted  
4-aza-5.alpha.-cholestan-3-ones and related 4-aza-5.alpha.-androstan-3-  
one compounds which are useful in the treatment of acne vulgaris in  
combination with at least one agent selected from an antibacterial,  
keratolytic, and/or an anti-inflammatory.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=&gt; d kwic

L24 ANSWER 1 OF 1 USPATFULL on STN

- TI Combination method of treating **acne** using 4-AZA-5.alpha.-cholestan-ones and 4-AZA-5.alpha.-androstan-ones as selective 5.alpha.-reductase inhibitors with anti-bacterial, keratolytic, or anti-inflammatory agents
- SUMM The term "oxo", as used herein, indicates an oxo **radical** which can occur in any stable point along the carbon chain resulting in a formyl group, if at the end. . . .
- SUMM The term "heteroaryl" as used herein, is intended to include a 5, 6 or 7 membered heteroaromatic **radical** containing at least one member selected from the group consisting of: one ring oxygen atom, one ring sulfur atom, 1-4. . . .
- SUMM . . . the like, for use as the dosage form. Where a basic group is present, i.e., amino or a basic heteroaryl **radical** such as, e.g., 4-pyridyl, an acidic salt, i.e., hydrochloride, hydrobromide, acetate, pamoate, and the like, can be used as the. . . .
- SUMM . . . starting 3-acetoxy-cholest-5-ene I (see Example 1 for synthesis) is oxidized to the corresponding 5-en-7-one II by treatment with hydrogen t-butyl **peroxide** and chromium hexacarbonyl in e.g., acetonitrile, at reflux. The C.sub.1 -C.sub.4 alkyl group, designated Alk, e.g., methyl, can be introduced. . . .
- SUMM azithromycin, carbomycin, clarithromycin, **erythromycin**, **erythromycin** acistrate, **erythromycin** estolate, **erythromycin** glucoheptonate, **erythromycin** lactobionate, **erythromycin** propionate, **erythromycin** stearate, josamycin, leucomycins, midecamycins, miokamycin, oleandomycin, primycin, rokitamycin, rosaramicin, roxithromycin, spiramycin, troleandomycin
- SUMM acedapsone, acediasulfone, acetosulfone sodium, **dapsone**, diathymosulfone, glucosulfone sodium, solasulfone, succisulfone, sulfanilic acid, p-sulfanilylbenzylamine, p,p'-sulfonyldianiline-N,N'-digalactoside, sulfoxone sodium, thiazolsulfone
- SUMM cycloserine, mupirocin, tuberin, clofoctol, hexedine, methenamine, methenamine anhydromethylene-citrate, methenamine hippurate, methenamine mandelate, methenamine sulfosalicylate, nitroxoline, xibornol and benzoyl **peroxide**.
- SUMM Very useful antibacterials in the invention method are the following: clindamycin, **erythromycin**, tetracycline, benzoyl **peroxide** meclocycline, chloramphenicol, neomycin, metronidazole, and OPC 7251 (Otsuka).
- SUMM . . . compound that displays properties of a keratolytic and can in some instances also display properties of an antibacterial, e.g., benzoyl **peroxide**. Keratolytics act by improving inflammatory and/or noninflammatory acne lesions by reducing the population of P. acnes and facilitating a decrease. . . .
- SUMM For example, a compound of Formula I, e.g., 4,7-beta-dimethyl-4-aza-5-alpha-cholestan-3-one, and antibacterial, i.e., **erythromycin**, can be administered together in a single topical dosage formulation, or each active agent can be separately administered in a particular dosage formulation, e.g., as a 'separate oral (5.alpha.-reductase inhibitor) and topical **erythromycin** dosage formulations, or a topical dosage formulation of the antibacterial in combination with an oral dosage formulation of a compound. . . .
- SUMM One useful combination is **erythromycin** benzoyl **peroxide**, and a 5.alpha.-reductase 1 inhibitor, e.g., 3-oxo-4-aza-4,7.beta.-dimethyl-16.beta.-(4-chlorophenoxy)-5.alpha.-androstande.
- DETD . . . the previous synthesis, being 5.6 g (12.55 mmol) in 100 ml acetonitrile at 23.degree. C. was added 90% t-butyl hydrogen

**peroxide**, 3.958 g (43.92 mol), and 138 mg chromium hexacarbonyl. After refluxing the mixture under nitrogen for 24 hours, the reaction.

CLM What is claimed is:

. . . potassium, piperacillin, pivampicillin, propicillin, quinacillin, sulbenicillin, talampicillin, temocillin, ticarcillin; (e) lincosamides, including clindamycin, lincomycin; (f) macrolides, including azithromycin, carbomycin, clarithromycin, **erythromycin**, **erythromycin** acistrate, **erythromycin** estolate, **erythromycin** glucoheptonate, **erythromycin** lactobionate, **erythromycin** propionate, **erythromycin** stearate, josamycin, leucomycins, midecamycins, miokamycin, oleandomycin, primycin, rokitamycin, rosaramicin, roxithromycin, spiramycin, troleandomycin; (g) polypeptides, including amphomycin, bacitracin, capreomycin, colistin, enduracidin, . . . sulfanitran, sulfaperine, sulfaphenazole, sulfaproxyline, sulfapyrazine, sulfapyridine, sulfasomizole, sulfasymazine, sulfathiazole, sulfathiourea, sulfatolamide, sulfisomidine, sulfisoxazole; (m) sulfones, including acedapsone, acediasulfone, acetosulfone sodium, **dapsone**, diathymosulfone, glucosulfone sodium, solasulfone, succisulfone, sulfanilic acid, p-sulfanilylbenzylamine, p,p'-sulfonyldianiline-N,N'-digalactoside, sulfoxone sodium, thiazolsulfone; and (n) the group consisting of: cycloserine, mupirocin, tuberin, clofocetol, hexedine, methenamine, methenamine anhydromethylene-citrate, methenamine hippurate, methenamine mandelate, methenamine sulfosalicylate, nitroxoline, xibornol, benzoyl **peroxide**, or mixtures thereof.

19. The method of claim 18 wherein said antibacterial is clindamycin, OPC7251 (Otsuka) fluoroquinolone or **erythromycin**.

20. The method of claim 1 wherein said keratolytic agent is selected from the group consisting of algestone acetophenide, azelaic acid, benzoyl **peroxide**, benzoyl **peroxide/erythromycin**, cyoctol, dichloroacetic acid, metronidazole, motretinide, resorcinol, salicylic acid, sulfur, tetroquinone, alpha-hydroxy acids, glycolic acid, and mixtures thereof.

21. The method of claim 20 wherein said keratolytic agent is benzoyl **peroxide**, benzoyl **peroxide/erythromycin**, or salicylic acid.

=> d his

(FILE 'HOME' ENTERED AT 10:41:50 ON 27 JUL 2003)

FILE 'USPATFULL' ENTERED AT 10:42:24 ON 27 JUL 2003

L1	7243 S ACNE?
L2	118483 S PEROXIDE?
L3	1027 S DAPSONE?
L4	2062 S L1 AND L2
L5	64 S L3 AND L4
L6	25482 S BENZOYL PEROXIDE?
L7	34 S L5 AND L6
L8	41785 S FERROUS OR TRANSITIONAL METAL?
L9	4 S L7 AND L8
L10	2524243 S METHOD? OR PROCESS?
L11	25097 S L10 AND L6
L12	63 S L3 AND L11
L13	9188 S ACNE OR SKIN CARE

10/091,607

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal503sxd

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	Feb 24	PCTGEN now available on STN
NEWS	4	Feb 24	TEMA now available on STN
NEWS	5	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS	6	Feb 26	PCTFULL now contains images
NEWS	7	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS	8	Mar 24	PATDPAFULL now available on STN
NEWS	9	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS	10	Apr 11	Display formats in DGENE enhanced
NEWS	11	Apr 14	MEDLINE Reload
NEWS	12	Apr 17	Polymer searching in REGISTRY enhanced
NEWS	13	Jun 13	Indexing from 1947 to 1956 added to records in CA/CAPLUS
NEWS	14	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS	15	Apr 28	RDISCLOSURE now available on STN
NEWS	16	May 05	Pharmacokinetic information and systematic chemical names added to PHAR
NEWS	17	May 15	MEDLINE file segment of TOXCENTER reloaded
NEWS	18	May 15	Supporter information for ENCOMPAT and ENCOMPLIT updated
NEWS	19	May 19	Simultaneous left and right truncation added to WSCA
NEWS	20	May 19	RAPRA enhanced with new search field, simultaneous left and right truncation
NEWS	21	Jun 06	Simultaneous left and right truncation added to CBNB
NEWS	22	Jun 06	PASCAL enhanced with additional data
NEWS	23	Jun 20	2003 edition of the FSTA Thesaurus is now available
NEWS	24	Jun 25	HSDB has been reloaded
NEWS	25	Jul 16	Data from 1960-1976 added to RDISCLOSURE
NEWS	26	Jul 21	Identification of STN records implemented
NEWS	27	Jul 21	Polymer class term count added to REGISTRY
NEWS	28	Jul 22	INPADOC: Basic index (/BI) enhanced; Simultaneous Left and Right Truncation available
NEWS EXPRESS			April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

10/091,607

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 10:41:50 ON 27 JUL 2003

=> file uspatfull  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'USPATFULL' ENTERED AT 10:42:24 ON 27 JUL 2003  
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 24 Jul 2003 (20030724/PD)  
FILE LAST UPDATED: 24 Jul 2003 (20030724/ED)  
HIGHEST GRANTED PATENT NUMBER: US6598233  
HIGHEST APPLICATION PUBLICATION NUMBER: US2003140390  
CA INDEXING IS CURRENT THROUGH 24 Jul 2003 (20030724/UPCA).  
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 24 Jul 2003 (20030724/PD)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2003  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2003

>>> USPAT2 is now available. USPATFULL contains full text of the <<<  
>>> original, i.e., the earliest published granted patents or <<<  
>>> applications. USPAT2 contains full text of the latest US <<<  
>>> publications, starting in 2001, for the inventions covered in <<<  
>>> USPATFULL. A USPATFULL record contains not only the original <<<  
>>> published document but also a list of any subsequent <<<  
>>> publications. The publication number, patent kind code, and <<<  
>>> publication date for all the US publications for an invention <<<  
>>> are displayed in the PI (Patent Information) field of USPATFULL <<<  
>>> records and may be searched in standard search fields, e.g., /PN, <<<  
>>> /PK, etc. <<<

>>> USPATFULL and USPAT2 can be accessed and searched together <<<  
>>> through the new cluster USPATALL. Type FILE USPATALL to <<<  
>>> enter this cluster. <<<  
>>> <<<  
>>> Use USPATALL when searching terms such as patent assignees, <<<  
>>> classifications, or claims, that may potentially change from <<<  
>>> the earliest to the latest publication. <<<

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s acne?  
L1 7243 ACNE?

=> s peroxide?  
L2 118483 PEROXIDE?

=> s dapsone?  
L3 1027 DAPSONE?

=> s l1 and l2  
L4 2062 L1 AND L2

10/091,607

=> s 13 and 14

L5 64 L3 AND L4

=> s benzoyl peroxide?

69142 BENZOYL

118483 PEROXIDE?

L6 25482 BENZOYL PEROXIDE?

(BENZOYL(W) PEROXIDE?)

=> s 15 and 16

L7 34 L5 AND L6

=> s ferrous or transitional metal?

40770 FERROUS

18227 TRANSITIONAL

1335032 METAL?

1070 TRANSITIONAL METAL?

(TRANSITIONAL(W) METAL?)

L8 41785 FERROUS OR TRANSITIONAL METAL?

=> s 17 and 18

L9 4 L7 AND L8

=> d 1-4 ibib abs

L9 ANSWER 1 OF 4 USPATFULL on STN

ACCESSION NUMBER: 2003:85867 USPATFULL

TITLE: Oral delivery formulation

INVENTOR(S): Compton, Bruce Jon, Lexington, MA, UNITED STATES

Solari, Nancy E., West Newton, MA, UNITED STATES

Flangan, Margaret A., Stow, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003059471	A1	20030327
APPLICATION INFO.:	US 2001-997277	A1	20011129 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-55560, filed on 6 Apr 1998, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-69501P	19971215 (60)
	US 1998-73867P	19980204 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Stephen J Gaudet, 68H Stiles Road, Salem, NH, 03079	
NUMBER OF CLAIMS:	42	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2950	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	Flakes containing drugs and methods for forming and using such flakes are provided.	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 2 OF 4 USPATFULL on STN

ACCESSION NUMBER: 2002:17328 USPATFULL

TITLE: Dha-pharmaceutical agent conjugates of taxanes

INVENTOR(S): Shashoua, Victor, Brookline, MA, UNITED STATES

Swindell, Charles, Merion, PA, UNITED STATES

Webb, Nigel, Bryn Mawr, PA, UNITED STATES

Bradley, Matthews, Layton, PA, UNITED STATES



	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002010208	A1	20020124
APPLICATION INFO.:	US 2001-846838	A1	20010501 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-135291, filed on 17 Aug 1998, ABANDONED Continuation of Ser. No. US 1996-651312, filed on 22 May 1996, GRANTED, Pat. No. US 5795909		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Edward R. Gates, Esq., Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA, 02210		
NUMBER OF CLAIMS:	19		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	14 Drawing Page(s)		
LINE COUNT:	2437		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides conjugates of cis-docosahexaenoic acid and pharmaceutical agents useful in treating noncentral nervous system conditions. Methods for selectively targeting pharmaceutical agents to desired tissues are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 3 OF 4 USPATFULL on STN

ACCESSION NUMBER: 2001:90260 USPATFULL  
 TITLE: Fatty acid-pharmaceutical agent conjugates  
 INVENTOR(S): Webb, Nigel L., Bryn Mawr, PA, United States  
 Bradley, Matthews O., Laytonsville, MD, United States  
 Swindell, Charles S., Merion, PA, United States  
 Shashoua, Victor E., Brookline, MA, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001002404	A1	20010531
	US 6576636	B2	20030610
APPLICATION INFO.:	US 2000-730450	A1	20001205 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1996-651428, filed on 22 May 1996, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Edward R. Gates, Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA, 02210		
NUMBER OF CLAIMS:	12		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	14 Drawing Page(s)		
LINE COUNT:	2511		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides conjugates of fatty acids and pharmaceutical agents useful in treating noncentral nervous system conditions. Methods for selectively targeting pharmaceutical agents to desired tissues are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 4 OF 4 USPATFULL on STN

ACCESSION NUMBER: 1998:98932 USPATFULL  
 TITLE: DHA-pharmaceutical agent conjugates of taxanes  
 INVENTOR(S): Shashoua, Victor E., Brookline, MA, United States  
 Swindell, Charles S., Merion, PA, United States  
 Webb, Nigel L., Bryn Mawr, PA, United States

10/091,607

PATENT ASSIGNEE(S): Bradley, Matthews O., Laytonsville, MD, United States  
Neuromedica, Inc., Conshohocken, PA, United States  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5795909		19980818
APPLICATION INFO.:	US 1996-651312		19960522 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Jarvis, William R. A.		
LEGAL REPRESENTATIVE:	Wolf, Greenfield & Sacks, P.C.		
NUMBER OF CLAIMS:	12		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	27 Drawing Figure(s); 14 Drawing Page(s)		
LINE COUNT:	2451		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides conjugates of cis-docosahexaenoic acid and taxanes useful in treating cell proliferative disorders. Conjugates of paclitaxel and docetaxel are preferred.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 10:41:50 ON 27 JUL 2003)

FILE 'USPATFULL' ENTERED AT 10:42:24 ON 27 JUL 2003

L1 7243 S ACNE?  
L2 118483 S PEROXIDE?  
L3 1027 S DAPSONE?  
L4 2062 S L1 AND L2  
L5 64 S L3 AND L4  
L6 25482 S BENZOYL PEROXIDE?  
L7 34 S L5 AND L6  
L8 41785 S FERROUS OR TRANSITIONAL METAL?  
L9 4 S L7 AND L8

=> s method? or process?

2100514 METHOD?

2017928 PROCESS?

L10 2524243 METHOD? OR PROCESS?

=> s l10 and l6

L11 25097 L10 AND L6

=> s l3 and l11

L12 63 L3 AND L11

=> s acne or skin care

6546 ACNE

170466 SKIN

171087 CARE

3574 SKIN CARE

(SKIN(W) CARE)

L13 9188 ACNE OR SKIN CARE

=> s l11 and l12

L14 63 L11 AND L12

=> s erythromycin

10/091,607

L15 6527 ERYTHROMYCIN

=> s l14 and l15

L16 52 L14 AND L15

=> d l16 not l15

L15 IS NOT VALID HERE

For an explanation, enter "HELP DISPLAY".

=> s l16 not l15

L17 0 L16 NOT L15

=> s l116 not l14

9 LL16

L18 9 LL16 NOT L14

=> d 1-9 ibib abs

L18 ANSWER 1 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2002:300965 USPATFULL

TITLE: Medical packaging substrate

INVENTOR(S): Reed, Amy B., Marietta, GA, UNITED STATES  
Bean, Karen H., Cumming, GA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002168508	A1	20021114
APPLICATION INFO.:	US 2001-976411	A1	20011012 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-240184P	20001013 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Neil C. Jones, Nelson Mullins Riley & Scarborough, Keenan Building, Third Floor, 1330 Lady Street, Columbia, SC, 29201	

NUMBER OF CLAIMS: 20

EXEMPLARY CLAIM: 1

LINE COUNT: 816

AB A polymer-impregnated paper-based web for use as a medical packaging bacteria barrier fabric is provided. The use of a particular type of polymer emulsion as the saturant provides the effective range of bacteria filtration while at the same time allowing the web to maintain its enhanced strength and delamination resistance that are required when such substrates are employed to wrap surgical trays, surgical instruments, medical appliances and the like prior to sterilization. The invention consists of a paper-containing medical packaging substrate that has been saturated with a polymer having a glass transition temperature of -20.degree. C. or less.

L18 ANSWER 2 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2002:171726 USPATFULL

TITLE: Self heat sealable packaging and a method for making same

INVENTOR(S): Bean, Karen H., Cumming, GA, UNITED STATES  
Stokes, Bruce G., Woodstock, GA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002090474	A1	20020711

10/091,607

APPLICATION INFO.: US 2001-976851 A1 20011012 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-249120P	20001116 (60)
	US 2000-240184P	20001013 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	John S. Pratt, Esq., KILPATRICK STOCKTON LLP, Suite 2800, 1100 Peachtree Street, N.E., Atlanta, GA, 30309-4530	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1772	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to saturants for fibrous webs that will confer upon those webs the ability to be heat scaled to many materials without compromising the drapability of the fibrous webs. The present invention is further directed to fibrous webs saturated with the saturant of the present invention and methods for saturating such webs. The invention is further directed to packages or containers comprising the saturated webs and methods of manufacturing such packages. The invention is further directed to temperature sensitive adhesive coatings that can be used with the saturated webs and a method for applying the coating.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 3 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2001:208582 USPATFULL  
TITLE: Liquid curable resin composition  
INVENTOR(S): Komiya, Zen, Tsukuba, Japan  
Yamaguchi, Yoshikazu, Tsukuba, Japan  
Watanabe, Tsuyoshi, Yokkaichi, Japan  
Ukachi, Takashi, Ushiku, Japan  
PATENT ASSIGNEE(S): DSM N.V., Heerlen, Netherlands (non-U.S. corporation)  
JSR Corporation, Tokyo, Japan (non-U.S. corporation)  
Japan Fine Coatings Co., Ltd., Tokyo, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6319603	B1	20011120
APPLICATION INFO.:	US 1999-260507		19990302 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 1997-NL498, filed on 1 Sep 1997		

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1996-231967	19960902
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Berman, Susan W.	
LEGAL REPRESENTATIVE:	Pillsbury Winthrop LLP	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1	
LINE COUNT:	726	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A liquid curable resin composition comprising (1) a (meth)acrylate polymer having a weight average molecular weight relative to polystyrene standard of at least about 5,000, (2) a ring-opening polymerizable monomer containing at least one epoxy group, and (3) a cationic

10/091,607

photopolymerization initiator is disclosed. The composition produces cured products which exhibit superior heat resistance, excellent mechanical strength, and superb adhesive characteristics, and is suitable for use as a photo-curable adhesive, a photo-curable sealing material, a resin for optical three-dimensional molding, and a coating material for optical fibers, and optical fiber ribbon matrix.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 4 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2001:188026 USPATFULL  
TITLE: Timing attack resistant cryptographic system  
INVENTOR(S): Vadekar, Ashok, Rockwood, Canada  
Lambert, Robert J., Cambridge, Canada

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001033655	A1	20011025
APPLICATION INFO.:	US 2001-761700	A1	20010118 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 1999-CA658, filed on 21 Jul 1999, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	CA 1998-2243761	19980721
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Finnegan, Henderson, Farabow,, Garrett & Dunner, L.L.P., 1300 I Street, N.W., Washington, DC, 20005-3315	
NUMBER OF CLAIMS:	6	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	7 Drawing Page(s)	
LINE COUNT:	322	

AB A method for determining a result of a group operation performed an integral number of times on a selected element of the group, the method comprises the steps of representing the integral number as a binary vector; initializing an intermediate element to the group identity element; selecting successive bits, beginning with a left most bit, of the vector. For each of the selected bits; performing the group operation on the intermediate element to derive a new intermediate element; replacing the intermediate element with the new intermediate element; performing the group operation on the intermediate element and an element, selected from the group consisting of: the group element if the selected bit is a one; and an inverse element of the group element if the selected bit is a zero; replacing the intermediate element with the new intermediate element. In a final step, performing the group operation on the intermediate value and the inverse element if the last selected bit is a zero; and replacing the intermediate element therewith, to obtain the result, whereby each of the bits of the integral is processed with substantially equal operations thereby minimizing timing attacks on the cryptographic system.

L18 ANSWER 5 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2001:91177 USPATFULL  
TITLE: Force sensor  
INVENTOR(S): Okada, Kazuhiro, Ageo-shi, Japan  
Taniguchi, Nobumitsu, Ageo-shi, Japan  
Morimoto, Hideo, Yamatokooryama-shi, Japan  
PATENT ASSIGNEE(S): WACOH CORPORATION (non-U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

10/091,607

PATENT INFORMATION:	US 2001003326	A1	20010614
	US 6530283	B2	20030311
APPLICATION INFO.:	US 2000-730429	A1	20001205 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1999-352645	19991213
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Ladas & Parry, 26 West 61st Street, New York, NY, 10023	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	24 Drawing Page(s)	
LINE COUNT:	1697	

AB An intermediate displacement board (120) composed of a metal plate is arranged on a printed circuit board (110) having electrode patterns (E1-E7) and then a strain generative body (130) composed of silicon rubber is arranged on top thereof. Then, the arrangement is fixed to the printed circuit board (110) with attachments (140). Depressing a displacement portion (133) causes a connecting portion (132) to be deflected and an electrode (F0) to be brought into contact with the electrodes (E1, E2) to make them conductive, thereby allowing the pushbutton switch to be turned ON. Depressing further the displacement portion (133) causes an elastic deformation portion (134) to be elastically deformed and crushed and the intermediate displacement board (120) to be pushed downward. The capacitance of capacitors (C3-C7), which are constituted by the electrodes (E3-E7) and the intermediate displacement board (120), are varied according to the depression of the intermediate displacement board (120). By detecting the variation in capacitance, it becomes possible to detect three-dimensional components of an applied force.

L18 ANSWER 6 OF 9 USPATFULL on STN

ACCESSION NUMBER:	2000:21107 USPATFULL
TITLE:	Facial tissue with reduced moisture penetration
INVENTOR(S) :	McFarland, Timothy Maurice, Neenah, WI, United States Drymalski, Michael Francis, Menasha, WI, United States Kaun, James Martin, Neenah, WI, United States Swails, Marvin Edsel, Appleton, WI, United States Sweeney, Eric Francis, Waupaca, WI, United States
PATENT ASSIGNEE(S) :	Kimberly-Clark Worldwide, Inc., Neenah, WI, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6027611		20000222
APPLICATION INFO.:	US 1996-638522		19960426 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Fortuna, Jose		
LEGAL REPRESENTATIVE:	Croft, Gregory E.		
NUMBER OF CLAIMS:	10		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)		
LINE COUNT:	521		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Facial tissue is rendered resistant to water penetration while retaining softness by treating the fibers with a sizing agent prior to forming the sheet, or topically after the sheet is formed. The resulting tissue prevents the user's hands from becoming wetted during nose care.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 7 OF 9 USPATFULL on STN

ACCESSION NUMBER: 94:60011 USPATFULL  
 TITLE: Process for making a hydraulically needled  
 superabsorbent composite material and article thereof  
 INVENTOR(S): McCormack, Ann L., Cumming, GA, United States  
 Radwanski, Fred R., Roswell, GA, United States  
 Everhart, Cherie H., Alpharetta, GA, United States  
 PATENT ASSIGNEE(S): Kimberly-Clark Corporation, Neenah, WI, United States  
 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5328759		19940712
APPLICATION INFO.:	US 1991-786437		19911101 (7)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Bell, James J.		
LEGAL REPRESENTATIVE:	Sidor, Karl V.		
NUMBER OF CLAIMS:	27		
EXEMPLARY CLAIM:	1,16		
NUMBER OF DRAWINGS:	15 Drawing Figure(s); 10 Drawing Page(s)		
LINE COUNT:	1187		

AB Disclosed is a process of making an superabsorbent composite material which contains a hydraulically-needled fibrous web and superabsorbent materials. The method includes the steps of providing a nonwoven fibrous web; hydraulically needling the nonwoven web to enhance its liquid distribution properties; and introducing dry superabsorbent materials into intimate bonding contact with at least one surface of the hydraulically needled fibrous web. Also disclosed is the superabsorbent nonwoven composite material made by the described process. The hydraulically needled fibrous web component of the material may contain pulp fibers, synthetic fibers, natural fibers, bicomponent fibers, continuous filaments or mixtures thereof. The superabsorbent composite material has a saturation capacity greater than about 500 percent and a wicking rate greater than about 12 centimeters per 15 minutes. The superabsorbent composite material may be used as a liquid management material in an absorbent product or absorbent structure.

L18 ANSWER 8 OF 9 USPATFULL on STN

ACCESSION NUMBER: 92:79515 USPATFULL  
 TITLE: Interblock dispersed-word memory architecture  
 INVENTOR(S): Hag, Ejaz U., Sunnyvale, CA, United States  
 PATENT ASSIGNEE(S): VLSI Technology, Inc., San Jose, CA, United States  
 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5150330		19920922
APPLICATION INFO.:	US 1991-722586		19910627 (7)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1990-469617, filed on 24 Jan 1990, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Fears, Terrell W.		
ASSISTANT EXAMINER:	Lane, Jack A.		
LEGAL REPRESENTATIVE:	Anderson, Clifton L.		
NUMBER OF CLAIMS:	10		
EXEMPLARY CLAIM:	1		

10/091,607

=> s 13 and 14

L5 64 L3 AND L4

=> s benzoyl peroxide?

69142 BENZOYL

118483 PEROXIDE?

L6 25482 BENZOYL PEROXIDE?

(BENZOYL (W) PEROXIDE?)

=> s 15 and 16

L7 34 L5 AND L6

=> s ferrous or transitional metal?

40770 FERROUS

18227 TRANSITIONAL

1335032 METAL?

1070 TRANSITIONAL METAL?

(TRANSITIONAL (W) METAL?)

L8 41785 FERROUS OR TRANSITIONAL METAL?

=> s 17 and 18

L9 4 L7 AND L8

=> d 1-4 ibib abs

L9 ANSWER 1 OF 4 USPATFULL on STN

ACCESSION NUMBER: 2003:85867 USPATFULL

TITLE: Oral delivery formulation

INVENTOR(S): Compton, Bruce Jon, Lexington, MA, UNITED STATES

Solari, Nancy E., West Newton, MA, UNITED STATES

Flangan, Margaret A., Stow, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003059471	A1	20030327
APPLICATION INFO.:	US 2001-997277	A1	20011129 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-55560, filed on 6 Apr 1998, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-69501P	19971215 (60)
	US 1998-73867P	19980204 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Stephen J Gaudet, 68H Stiles Road, Salem, NH, 03079	
NUMBER OF CLAIMS:	42	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2950	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	Flakes containing drugs and methods for forming and using such flakes are provided.	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 2 OF 4 USPATFULL on STN

ACCESSION NUMBER: 2002:17328 USPATFULL

TITLE: Dha-pharmaceutical agent conjugates of taxanes

INVENTOR(S): Shashoua, Victor, Brookline, MA, UNITED STATES

Swindell, Charles, Merion, PA, UNITED STATES

Webb, Nigel, Bryn Mawr, PA, UNITED STATES

Bradley, Matthews, Layton, PA, UNITED STATES



	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002010208	A1	20020124
APPLICATION INFO.:	US 2001-846838	A1	20010501 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-135291, filed on 17 Aug 1998, ABANDONED Continuation of Ser. No. US 1996-651312, filed on 22 May 1996, GRANTED, Pat. No. US 5795909		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Edward R. Gates, Esq., Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA, 02210		
NUMBER OF CLAIMS:	19		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	14 Drawing Page(s)		
LINE COUNT:	2437		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides conjugates of cis-docosaheptaenoic acid and pharmaceutical agents useful in treating noncentral nervous system conditions. Methods for selectively targeting pharmaceutical agents to desired tissues are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 3 OF 4 USPATFULL on STN

ACCESSION NUMBER:	2001:90260	USPATFULL
TITLE:	Fatty acid-pharmaceutical agent conjugates	
INVENTOR(S):	Webb, Nigel L., Bryn Mawr, PA, United States Bradley, Matthews O., Laytonsville, MD, United States Swindell, Charles S., Merion, PA, United States Shashoua, Victor E., Brookline, MA, United States	

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001002404	A1	20010531
	US 6576636	B2	20030610
APPLICATION INFO.:	US 2000-730450	A1	20001205 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1996-651428, filed on 22 May 1996, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Edward R. Gates, Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA, 02210		
NUMBER OF CLAIMS:	12		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	14 Drawing Page(s)		
LINE COUNT:	2511		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides conjugates of fatty acids and pharmaceutical agents useful in treating noncentral nervous system conditions. Methods for selectively targeting pharmaceutical agents to desired tissues are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 4 OF 4 USPATFULL on STN

ACCESSION NUMBER:	1998:98932	USPATFULL
TITLE:	DHA-pharmaceutical agent conjugates of taxanes	
INVENTOR(S):	Shashoua, Victor E., Brookline, MA, United States Swindell, Charles S., Merion, PA, United States Webb, Nigel L., Bryn Mawr, PA, United States	

10/091,607

PATENT ASSIGNEE(S): Bradley, Matthews O., Laytonsville, MD, United States  
Neuromedica, Inc., Conshohocken, PA, United States  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5795909		19980818
APPLICATION INFO.:	US 1996-651312		19960522 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Jarvis, William R. A.		
LEGAL REPRESENTATIVE:	Wolf, Greenfield & Sacks, P.C.		
NUMBER OF CLAIMS:	12		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	27 Drawing Figure(s); 14 Drawing Page(s)		
LINE COUNT:	2451		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides conjugates of cis-docosahexaenoic acid and taxanes useful in treating cell proliferative disorders. Conjugates of paclitaxel and docetaxel are preferred.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 10:41:50 ON 27 JUL 2003)

FILE 'USPATFULL' ENTERED AT 10:42:24 ON 27 JUL 2003

L1 7243 S ACNE?  
L2 118483 S PEROXIDE?  
L3 1027 S DAPSONE?  
L4 2062 S L1 AND L2  
L5 64 S L3 AND L4  
L6 25482 S BENZOYL PEROXIDE?  
L7 34 S L5 AND L6  
L8 41785 S FERROUS OR TRANSITIONAL METAL?  
L9 4 S L7 AND L8

=> s method? or process?

2100514 METHOD?

2017928 PROCESS?

L10 2524243 METHOD? OR PROCESS?

=> s l10 and l6

L11 25097 L10 AND L6

=> s l3 and l11

L12 63 L3 AND L11

=> s acne or skin care

6546 ACNE

170466 SKIN

171087 CARE

3574 SKIN CARE

(SKIN(W) CARE)

L13 9188 ACNE OR SKIN CARE

=> s l11 and l12

L14 63 L11 AND L12

=> s erythromycin

10/091,607

L15 6527 ERYTHROMYCIN

=> s l14 and l15

L16 52 L14 AND L15

=> d l16 not l15

L15 IS NOT VALID HERE

For an explanation, enter "HELP DISPLAY".

=> s l16 not l15

L17 0 L16 NOT L15

=> s l116 not l14

9 LL16

L18 9 LL16 NOT L14

=> d 1-9 ibib abs

L18 ANSWER 1 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2002:300965 USPATFULL

TITLE: Medical packaging substrate

INVENTOR(S): Reed, Amy B., Marietta, GA, UNITED STATES  
Bean, Karen H., Cumming, GA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002168508	A1	20021114
APPLICATION INFO.:	US 2001-976411	A1	20011012 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-240184P	20001013 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Neil C. Jones, Nelson Mullins Riley & Scarborough, Keenan Building, Third Floor, 1330 Lady Street, Columbia, SC, 29201	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
LINE COUNT:	816	

AB A polymer-impregnated paper-based web for use as a medical packaging bacteria barrier fabric is provided. The use of a particular type of polymer emulsion as the saturant provides the effective range of bacteria filtration while at the same time allowing the web to maintain its enhanced strength and delamination resistance that are required when such substrates are employed to wrap surgical trays, surgical instruments, medical appliances and the like prior to sterilization. The invention consists of a paper-containing medical packaging substrate that has been saturated with a polymer having a glass transition temperature of -20.degree. C. or less.

L18 ANSWER 2 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2002:171726 USPATFULL

TITLE: Self heat sealable packaging and a method for making same

INVENTOR(S): Bean, Karen H., Cumming, GA, UNITED STATES  
Stokes, Bruce G., Woodstock, GA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002090474	A1	20020711

10/091,607

APPLICATION INFO.: US 2001-976851 A1 20011012 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-249120P	20001116 (60)
	US 2000-240184P	20001013 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	John S. Pratt, Esq., KILPATRICK STOCKTON LLP, Suite 2800, 1100 Peachtree Street, N.E., Atlanta, GA, 30309-4530	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1772	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to saturants for fibrous webs that will confer upon those webs the ability to be heat scaled to many materials without compromising the drapability of the fibrous webs. The present invention is further directed to fibrous webs saturated with the saturant of the present invention and methods for saturating such webs. The invention is further directed to packages or containers comprising the saturated webs and methods of manufacturing such packages. The invention is further directed to temperature sensitive adhesive coatings that can be used with the saturated webs and a method for applying the coating.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 3 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2001:208582 USPATFULL  
TITLE: Liquid curable resin composition  
INVENTOR(S): Komiya, Zen, Tsukuba, Japan  
Yamaguchi, Yoshikazu, Tsukuba, Japan  
Watanabe, Tsuyoshi, Yokkaichi, Japan  
Ukachi, Takashi, Ushiku, Japan  
PATENT ASSIGNEE(S): DSM N.V., Heerlen, Netherlands (non-U.S. corporation)  
JSR Corporation, Tokyo, Japan (non-U.S. corporation)  
Japan Fine Coatings Co., Ltd., Tokyo, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6319603	B1	20011120
APPLICATION INFO.:	US 1999-260507		19990302 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 1997-NL498, filed on 1 Sep 1997		

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1996-231967	19960902
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Berman, Susan W.	
LEGAL REPRESENTATIVE:	Pillsbury Winthrop LLP	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1	
LINE COUNT:	726	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A liquid curable resin composition comprising (1) a (meth)acrylate polymer having a weight average molecular weight relative to polystyrene standard of at least about 5,000, (2) a ring-opening polymerizable monomer containing at least one epoxy group, and (3) a cationic

10/091,607

photopolymerization initiator is disclosed. The composition produces cured products which exhibit superior heat resistance, excellent mechanical strength, and superb adhesive characteristics, and is suitable for use as a photo-curable adhesive, a photo-curable sealing material, a resin for optical three-dimensional molding, and a coating material for optical fibers, and optical fiber ribbon matrix.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 4 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2001:188026 USPATFULL  
TITLE: Timing attack resistant cryptographic system  
INVENTOR(S): Vadekar, Ashok, Rockwood, Canada  
Lambert, Robert J., Cambridge, Canada

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001033655	A1	20011025
APPLICATION INFO.:	US 2001-761700	A1	20010118 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 1999-CA658, filed on 21 Jul 1999, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	CA 1998-2243761	19980721
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Finnegan, Henderson, Farabow,, Garrett & Dunner, L.L.P., 1300 I Street, N.W., Washington, DC, 20005-3315	
NUMBER OF CLAIMS:	6	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	7 Drawing Page(s)	
LINE COUNT:	322	

AB A method for determining a result of a group operation performed an integral number of times on a selected element of the group, the method comprises the steps of representing the integral number as a binary vector; initializing an intermediate element to the group identity element; selecting successive bits, beginning with a left most bit, of the vector. For each of the selected bits; performing the group operation on the intermediate element to derive a new intermediate element; replacing the intermediate element with the new intermediate element; performing the group operation on the intermediate element and an element, selected from the group consisting of: the group element if the selected bit is a one; and an inverse element of the group element if the selected bit is a zero; replacing the intermediate element with the new intermediate element. In a final step, performing the group operation on the intermediate value and the inverse element if the last selected bit is a zero; and replacing the intermediate element therewith, to obtain the result, whereby each of the bits of the integral is processed with substantially equal operations thereby minimizing timing attacks on the cryptographic system.

L18 ANSWER 5 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2001:91177 USPATFULL  
TITLE: Force sensor  
INVENTOR(S): Okada, Kazuhiro, Ageo-shi, Japan  
Taniguchi, Nobumitsu, Ageo-shi, Japan  
Morimoto, Hideo, Yamatokooryama-shi, Japan  
PATENT ASSIGNEE(S): WACOH CORPORATION (non-U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

10/091,607

PATENT INFORMATION:	US 2001003326	A1	20010614
	US 6530283	B2	20030311
APPLICATION INFO.:	US 2000-730429	A1	20001205 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1999-352645	19991213
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Ladas & Parry, 26 West 61st Street, New York, NY, 10023	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	24 Drawing Page(s)	
LINE COUNT:	1697	

AB An intermediate displacement board (120) composed of a metal plate is arranged on a printed circuit board (110) having electrode patterns (E1-E7) and then a strain generative body (130) composed of silicon rubber is arranged on top thereof. Then, the arrangement is fixed to the printed circuit board (110) with attachments (140). Depressing a displacement portion (133) causes a connecting portion (132) to be deflected and an electrode (F0) to be brought into contact with the electrodes (E1, E2) to make them conductive, thereby allowing the pushbutton switch to be turned ON. Depressing further the displacement portion (133) causes an elastic deformation portion (134) to be elastically deformed and crushed and the intermediate displacement board (120) to be pushed downward. The capacitance of capacitors (C3-C7), which are constituted by the electrodes (E3-E7) and the intermediate displacement board (120), are varied according to the depression of the intermediate displacement board (120). By detecting the variation in capacitance, it becomes possible to detect three-dimensional components of an applied force.

L18 ANSWER 6 OF 9 USPATFULL on STN

ACCESSION NUMBER:	2000:21107 USPATFULL
TITLE:	Facial tissue with reduced moisture penetration
INVENTOR(S):	McFarland, Timothy Maurice, Neenah, WI, United States Drymalski, Michael Francis, Menasha, WI, United States Kaun, James Martin, Neenah, WI, United States Swails, Marvin Edsel, Appleton, WI, United States Sweeney, Eric Francis, Waupaca, WI, United States
PATENT ASSIGNEE(S):	Kimberly-Clark Worldwide, Inc., Neenah, WI, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6027611		20000222
APPLICATION INFO.:	US 1996-638522		19960426 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Fortuna, Jose		
LEGAL REPRESENTATIVE:	Croft, Gregory E.		
NUMBER OF CLAIMS:	10		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)		
LINE COUNT:	521		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Facial tissue is rendered resistant to water penetration while retaining softness by treating the fibers with a sizing agent prior to forming the sheet, or topically after the sheet is formed. The resulting tissue prevents the user's hands from becoming wetted during nose care.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 7 OF 9 USPATFULL on STN

ACCESSION NUMBER: 94:60011 USPATFULL  
 TITLE: Process for making a hydraulically needled  
 superabsorbent composite material and article thereof  
 INVENTOR(S): McCormack, Ann L., Cumming, GA, United States  
 Radwanski, Fred R., Roswell, GA, United States  
 Everhart, Cherie H., Alpharetta, GA, United States  
 PATENT ASSIGNEE(S): Kimberly-Clark Corporation, Neenah, WI, United States  
 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5328759		19940712
APPLICATION INFO.:	US 1991-786437		19911101 (7)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Bell, James J.		
LEGAL REPRESENTATIVE:	Sidor, Karl V.		
NUMBER OF CLAIMS:	27		
EXEMPLARY CLAIM:	1,16		
NUMBER OF DRAWINGS:	15 Drawing Figure(s); 10 Drawing Page(s)		
LINE COUNT:	1187		

AB Disclosed is a process of making an superabsorbent composite material which contains a hydraulically-needled fibrous web and superabsorbent materials. The method includes the steps of providing a nonwoven fibrous web; hydraulically needling the nonwoven web to enhance its liquid distribution properties; and introducing dry superabsorbent materials into intimate bonding contact with at least one surface of the hydraulically needled fibrous web. Also disclosed is the superabsorbent nonwoven composite material made by the described process. The hydraulically needled fibrous web component of the material may contain pulp fibers, synthetic fibers, natural fibers, bicomponent fibers, continuous filaments or mixtures thereof. The superabsorbent composite material has a saturation capacity greater than about 500 percent and a wicking rate greater than about 12 centimeters per 15 minutes. The superabsorbent composite material may be used as a liquid management material in an absorbent product or absorbent structure.

L18 ANSWER 8 OF 9 USPATFULL on STN

ACCESSION NUMBER: 92:79515 USPATFULL  
 TITLE: Interblock dispersed-word memory architecture  
 INVENTOR(S): Hag, Ejaz U., Sunnyvale, CA, United States  
 PATENT ASSIGNEE(S): VLSI Technology, Inc., San Jose, CA, United States  
 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5150330		19920922
APPLICATION INFO.:	US 1991-722586		19910627 (7)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1990-469617, filed on 24 Jan 1990, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Fears, Terrell W.		
ASSISTANT EXAMINER:	Lane, Jack A.		
LEGAL REPRESENTATIVE:	Anderson, Clifton L.		
NUMBER OF CLAIMS:	10		
EXEMPLARY CLAIM:	1		

10/091,607

NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)  
LINE COUNT: 532

AB A static random access memory (SRAM) employs a modified divided word architecture in which each address selects cells from plural blocks. Thus, each word is dispersed among multiple blocks, rather than being confined to a single block as in conventional divided word architectures. More specifically, the blocks are divided among four quadrants of the array and data pads (or ports) are arranged on opposite sides of the array. This architecture causes each word to be divided among all four quadrants. Each quadrant is coupled via a respective data bus to the data ports adjacent to the quadrant. This arrangement reduces data path lengths within the SRAM, improving overall access times.

L18 ANSWER 9 OF 9 USPATFULL on STN

ACCESSION NUMBER: 75:67012 USPATFULL  
TITLE: Fabricating apparatus for twin-sheets  
INVENTOR(S): Brown, Gaylord W., Beaverton, MI, United States  
PATENT ASSIGNEE(S): Koehring Company, Milwaukee, WI, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 3925140		19751209
APPLICATION INFO.:	US 1973-341850		19730316 (5)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Weston, Caleb		
NUMBER OF CLAIMS:	3		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	9 Drawing Figure(s); 8 Drawing Page(s)		
LINE COUNT:	857		

AB Apparatus and methods for fabricating a hollow plastic object from a pair of heat-fusible, thermoplastic sheets which are serially moved in a common horizontal plane from a heating station to a mold mechanism at a forming station. At the forming station, one of the sheets is received by a mold which is then moved vertically to move the sheet out of the plane to a position juxtaposed with a following sheet when the latter arrives at the forming station. At least one of the sheets is differential pressure molded after arrival at the forming station and the sheets are then vertically moved together and fused to form the object.

=>

=> s acne/ti

L19 230 ACNE/TI

=> d his

(FILE 'HOME' ENTERED AT 10:41:50 ON 27 JUL 2003)

FILE 'USPATFULL' ENTERED AT 10:42:24 ON 27 JUL 2003

L1 7243 S ACNE?  
L2 118483 S PEROXIDE?  
L3 1027 S DAPSONE?  
L4 2062 S L1 AND L2  
L5 64 S L3 AND L4  
L6 25482 S BENZOYL PEROXIDE?  
L7 34 S L5 AND L6  
L8 41785 S FERROUS OR TRANSITIONAL METAL?



10/091,607

L9 4 S L7 AND L8  
L10 2524243 S METHOD? OR PROCESS?  
L11 25097 S L10 AND L6  
L12 63 S L3 AND L11  
L13 9188 S ACNE OR SKIN CARE  
L14 63 S L11 AND L12  
L15 6527 S ERYTHROMYCIN  
L16 52 S L14 AND L15  
L17 0 S L16 NOT L15  
L18 9 S L16 NOT L14  
L19 230 S ACNE/TI

=> s l19 and l2

L20 121 L19 AND L2

=> s l20 and l3

L21 5 L20 AND L3

=> s l21 not l15

L22 0 L21 NOT L15

=> s l21 and l15

L23 5 L21 AND L15

=> d 1-5 ibib abs

L23 ANSWER 1 OF 5 USPATFULL on STN

ACCESSION NUMBER: 2002:332478 USPATFULL

TITLE: Acne patch

INVENTOR(S): Buseman, Teri, Minnetonka, MN, United States  
Rolf, David, Eden Prairie, MN, United States  
McWhorter, Daniel M., Eagan, MN, United States

PATENT ASSIGNEE(S): Lec Tec Corporation, Minnetonka, MN, United States  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6495158	B1	20021217
APPLICATION INFO.:	US 2001-766885		20010119 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Dees, Jos' G.		
ASSISTANT EXAMINER:	Haghighatian, Mina		
LEGAL REPRESENTATIVE:	Schwegman, Lundberg, Woessner & Kluth, P.A.		
NUMBER OF CLAIMS:	77		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	10 Drawing Figure(s); 5 Drawing Page(s)		
LINE COUNT:	1816		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An adhesive patch is provided wherein the patch includes a flexible backing having a front side and a back side. The patch also includes a therapeutic formulation positioned on and in at least a portion of the front side of the backing such that the therapeutic formulation is partially embedded in at least a portion of the front side of the backing. At least a portion of the backing is treated with a hydrophobic sizing agent such that the portion of the backing that is treated with the hydrophobic sizing agent has a surface energy of about 20 dynes/cm.sup.2 to about 65 dynes/cm.sup.2. The therapeutic formulation includes a topical acne drug, a solvent that dissolves the topical acne drug, and a pressure sensitive adhesive.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

10/091,607

L23 ANSWER 2 OF 5 USPATFULL on STN

ACCESSION NUMBER: 97:118083 USPATFULL  
TITLE: Method for treating **acne**  
INVENTOR(S): Peck, Gary L., Silver Spring, MD, United States  
PATENT ASSIGNEE(S): The United States of America as represented by the  
Department of Health and Human Services, Washington,  
DC, United States (U.S. government)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5698593		19971216
APPLICATION INFO.:	US 1993-47007		19930415 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1991-735113, filed on 24 Jul 1991, now abandoned which is a continuation of Ser. No. US 1988-186260, filed on 26 Apr 1988, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Weddington, Kevin E.		
LEGAL REPRESENTATIVE:	Hyman, Laurence J. Office of Technology Transfer, NIH		
NUMBER OF CLAIMS:	11		
EXEMPLARY CLAIM:	1		
LINE COUNT:	393		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Nodulocystic and conglobate acne in humans can be alleviated by the oral administration of 13-cis-retinoic acid or a derivative thereof. The active ingredient is administered in a dosage of from about 1.5 to about 3 mg/kg of body weight per day for a period of from about two to about four weeks.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L23 ANSWER 3 OF 5 USPATFULL on STN

ACCESSION NUMBER: 96:70456 USPATFULL  
TITLE: Combination method of treating **acne** using  
4-AZA-5.alpha.-cholestan-ones and 4-AZA-5.alpha.-  
androstan-ones as selective 5.alpha.-reductase  
inhibitors with anti-bacterial, keratolytic, or  
anti-inflammatory agents  
INVENTOR(S): Waldstreicher, Joanne, Scotch Plains, NJ, United States  
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5543417		19960806
APPLICATION INFO.:	US 1994-327078		19941021 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Killos, Paul J.		
LEGAL REPRESENTATIVE:	Fitch, Catherine D., North, Robert J., Winokur, Melvin		
NUMBER OF CLAIMS:	31		
EXEMPLARY CLAIM:	1		
LINE COUNT:	3981		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Described is a combination method using selective inhibitors of 5.alpha.-reductase 1 and/or 2 including 7.beta.-substituted 4-aza-5.alpha.-cholestan-3-ones and related 4-aza-5.alpha.-androstan-3-one compounds which are useful in the treatment of acne vulgaris in combination with at least one agent selected from an antibacterial, keratolytic, and/or an anti-inflammatory.

10/091,607

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L23 ANSWER 4 OF 5 USPATFULL on STN

ACCESSION NUMBER: 89:97369 USPATFULL  
TITLE: Topical transretinoids for treatment of **acne**  
and skin diseases  
INVENTOR(S): Parish, Harlie A., Memphis, TN, United States  
Purcell, William P., Memphis, TN, United States  
PATENT ASSIGNEE(S): Molecular Design International, Memphis, TN, United  
States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4885311		19891205
APPLICATION INFO.:	US 1987-67536		19870629 (7)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Lone, Werren B.		
ASSISTANT EXAMINER:	Clarke, Vera C.		
LEGAL REPRESENTATIVE:	Waldron & Associates		
NUMBER OF CLAIMS:	14		
EXEMPLARY CLAIM:	1,3		
LINE COUNT:	405		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Esters and amides of 13-trans-retinoic acid are disclosed which are used  
for the treatment of acne and skin diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L23 ANSWER 5 OF 5 USPATFULL on STN

ACCESSION NUMBER: 87:47047 USPATFULL  
TITLE: Topical prodrugs for treatment of **acne** and  
skin diseases  
INVENTOR(S): Parish, Harlie A., Memphis, TN, United States  
Purcell, William P., Memphis, TN, United States  
PATENT ASSIGNEE(S): Molecular Design International, Memphis, TN, United  
States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4677120		19870630
APPLICATION INFO.:	US 1985-760881		19850731 (6)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Lone, Werren B.		
ASSISTANT EXAMINER:	Clarke, Vera C.		
LEGAL REPRESENTATIVE:	Waldron, James S.		
NUMBER OF CLAIMS:	14		
EXEMPLARY CLAIM:	1,3		
LINE COUNT:	623		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Esters and amides of 13-cis-retinoic acid are disclosed which are used  
for the treatment of acne and skin diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 10:41:50 ON 27 JUL 2003)

FILE 'USPATFULL' ENTERED AT 10:42:24 ON 27 JUL 2003

10/091,607

L1 7243 S ACNE?  
L2 118483 S PEROXIDE?  
L3 1027 S DAPSONE?  
L4 2062 S L1 AND L2  
L5 64 S L3 AND L4  
L6 25482 S BENZOYL PEROXIDE?  
L7 34 S L5 AND L6  
L8 41785 S FERROUS OR TRANSITIONAL METAL?  
L9 4 S L7 AND L8  
L10 2524243 S METHOD? OR PROCESS?  
L11 25097 S L10 AND L6  
L12 63 S L3 AND L11  
L13 9188 S ACNE OR SKIN CARE  
L14 63 S L11 AND L12  
L15 6527 S ERYTHROMYCIN  
L16 52 S L14 AND L15  
L17 0 S L16 NOT L15  
L18 9 S LL16 NOT L14  
L19 230 S ACNE/TI  
L20 121 S L19 AND L2  
L21 5 S L20 AND L3  
L22 0 S L21 NOT L15  
L23 5 S L21 AND L15

=> s l23 and radical?

206537 RADICAL?

L24 1 L23 AND RADICAL?

=> d 1 ibib abs

L24 ANSWER 1 OF 1 USPATFULL on STN

ACCESSION NUMBER: 96:70456 USPATFULL

TITLE: Combination method of treating acne using  
4-AZA-5.alpha.-cholestan-ones and 4-AZA-5.alpha.-  
androstan-ones as selective 5.alpha.-reductase  
inhibitors with anti-bacterial, keratolytic, or  
anti-inflammatory agents

INVENTOR(S): Waldstreicher, Joanne, Scotch Plains, NJ, United States

PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5543417		19960806
APPLICATION INFO.:	US 1994-327078		19941021 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Killos, Paul J.		
LEGAL REPRESENTATIVE:	Fitch, Catherine D., North, Robert J., Winokur, Melvin		
NUMBER OF CLAIMS:	31		
EXEMPLARY CLAIM:	1		
LINE COUNT:	3981		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Described is a combination method using selective inhibitors of  
5.alpha.-reductase 1 and/or 2 including 7.beta.-substituted  
4-aza-5.alpha.-cholestan-3-ones and related 4-aza-5.alpha.-androstan-3-  
one compounds which are useful in the treatment of acne vulgaris in  
combination with at least one agent selected from an antibacterial,  
keratolytic, and/or an anti-inflammatory.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=&gt; d kwic

L24 ANSWER 1 OF 1 USPATFULL on STN

TI Combination method of treating **acne** using 4-AZA-5.alpha.-cholestan-ones and 4-AZA-5.alpha.-androstan-ones as selective 5.alpha.-reductase inhibitors with anti-bacterial, keratolytic, or anti-inflammatory agents

SUMM The term "oxo", as used herein, indicates an oxo **radical** which can occur in any stable point along the carbon chain resulting in a formyl group, if at the end. . . .

SUMM The term "heteroaryl" as used herein, is intended to include a 5, 6 or 7 membered heteroaromatic **radical** containing at least one member selected from the group consisting of: one ring oxygen atom, one ring sulfur atom, 1-4. . . .

SUMM . . . the like, for use as the dosage form. Where a basic group is present, i.e., amino or a basic heteroaryl **radical** such as, e.g., 4-pyridyl, an acidic salt, i.e., hydrochloride, hydrobromide, acetate, pamoate, and the like, can be used as the. . . .

SUMM . . . starting 3-acetoxy-cholest-5-ene I (see Example 1 for synthesis) is oxidized to the corresponding 5-en-7-one II by treatment with hydrogen t-butyl **peroxide** and chromium hexacarbonyl in e.g., acetonitrile, at reflux. The C.sub.1 -C.sub.4 alkyl group, designated Alk, e.g., methyl, can be introduced. . . .

SUMM azithromycin, carbomycin, clarithromycin, **erythromycin**, **erythromycin** acistrate, **erythromycin** estolate, **erythromycin** glucoheptonate, **erythromycin** lactobionate, **erythromycin** propionate, **erythromycin** stearate, josamycin, leucomycins, midecamycins, miokamycin, oleandomycin, primycin, rokitamycin, rosaramicin, roxithromycin, spiramycin, troleandomycin

SUMM acedapsone, acediasulfone, acetosulfone sodium, **dapsone**, diathymosulfone, glucosulfone sodium, solasulfone, succisulfone, sulfanilic acid, p-sulfanilylbenzylamine, p,p'-sulfonyldianiline-N,N'-digalactoside, sulfoxone sodium, thiazolsulfone

SUMM cycloserine, mupirocin, tuberin, clofocetol, hexedine, methenamine, methenamine anhydromethylene-citrate, methenamine hippurate, methenamine mandelate, methenamine sulfosalicylate, nitroxoline, xibornol and benzoyl **peroxide**.

SUMM Very useful antibacterials in the invention method are the following: clindamycin, **erythromycin**, tetracycline, benzoyl **peroxide** meclocycline, chloramphenicol, neomycin, metronidazole, and OPC 7251 (Otsuka).

SUMM . . . compound that displays properties of a keratolytic and can in some instances also display properties of an antibacterial, e.g., benzoyl **peroxide**. Keratolytics act by improving inflammatory and/or noninflammatory acne lesions by reducing the population of P. acnes and facilitating a decrease. . . .

SUMM For example, a compound of Formula I, e.g., 4,7-beta-dimethyl-4-aza-5-alpha-cholestan-3-one, and antibacterial, i.e., **erythromycin**, can be administered together in a single topical dosage formulation, or each active agent can be separately administered in a particular dosage formulation, e.g., as a 'separate oral (5.alpha.-reductase inhibitor) and topical **erythromycin** dosage formulations, or a topical dosage formulation of the antibacterial in combination with an oral dosage formulation of a compound. . . .

SUMM One useful combination is **erythromycin** benzoyl **peroxide**, and a 5.alpha.-reductase 1 inhibitor, e.g., 3-oxo-4-aza-4,7.beta.-dimethyl-16.beta.-(4-chlorophenoxy)-5.alpha.-androstande.

DETD . . . the previous synthesis, being 5.6 g (12.55 mmol) in 100 ml acetonitrile at 23.degree. C. was added 90% t-butyl hydrogen

**peroxide**, 3.958 g (43.92 mol), and 138 mg chromium hexacarbonyl. After refluxing the mixture under nitrogen for 24 hours, the reaction.

CLM What is claimed is:

. . . potassium, piperacillin, pivampicillin, propicillin, quinacillin, sulbenicillin, talampicillin, temocillin, ticarcillin; (e) lincosamides, including clindamycin, lincomycin; (f) macrolides, including azithromycin, carbomycin, clarithromycin, **erythromycin**, **erythromycin** acistrate, **erythromycin** estolate, **erythromycin** glucoheptonate, **erythromycin** lactobionate, **erythromycin** propionate, **erythromycin** stearate, josamycin, leucomycins, midecamycins, miokamycin, oleandomycin, primycin, rokitamycin, rosaramicin, roxithromycin, spiramycin, troleandomycin; (g) polypeptides, including amphomycin, bacitracin, capreomycin, colistin, enduracidin, . . . sulfanitran, sulfaperine, sulfaphenazole, sulfaproxyline, sulfapyrazine, sulfapyridine, sulfasomizole, sulfasymazine, sulfathiazole, sulfathiourea, sulfatolamide, sulfisomidine, sulfisoxazole; (m) sulfones, including acedapsone, acediasulfone, acetosulfone sodium, **dapsone**, diathymosulfone, glucosulfone sodium, solasulfone, succisulfone, sulfanilic acid, p-sulfanilylbenzylamine, p,p'-sulfonyldianiline-N,N'-digalactoside, sulfoxone sodium, thiazolsulfone; and (n) the group consisting of: cycloserine, mupirocin, tuberin, clofocetol, hexedine, methenamine, methenamine anhydromethylene-citrate, methenamine hippurate, methenamine mandelate, methenamine sulfosalicylate, nitroxoline, xibornol, benzoyl **peroxide**, or mixtures thereof.

19. The method of claim 18 wherein said antibacterial is clindamycin, OPC7251 (Otsuka) fluoroquinolone or **erythromycin**.

20. The method of claim 1 wherein said keratolytic agent is selected from the group consisting of algestone acetophenide, azelaic acid, benzoyl **peroxide**, benzoyl **peroxide/erythromycin**, cyoctol, dichloroacetic acid, metronidazole, motretinide, resorcinol, salicylic acid, sulfur, tetroquinone, alpha-hydroxy acids, glycolic acid, and mixtures thereof.

21. The method of claim 20 wherein said keratolytic agent is benzoyl **peroxide**, benzoyl **peroxide/erythromycin**, or salicylic acid.

=> d his

(FILE 'HOME' ENTERED AT 10:41:50 ON 27 JUL 2003)

FILE 'USPATFULL' ENTERED AT 10:42:24 ON 27 JUL 2003

L1 7243 S ACNE?  
 L2 118483 S PEROXIDE?  
 L3 1027 S DAPSONE?  
 L4 2062 S L1 AND L2  
 L5 64 S L3 AND L4  
 L6 25482 S BENZOYL PEROXIDE?  
 L7 34 S L5 AND L6  
 L8 41785 S FERROUS OR TRANSITIONAL METAL?  
 L9 4 S L7 AND L8  
 L10 2524243 S METHOD? OR PROCESS?  
 L11 25097 S L10 AND L6  
 L12 63 S L3 AND L11  
 L13 9188 S ACNE OR SKIN CARE

10/091,607

L14 63 S L11 AND L12  
L15 6527 S ERYTHROMYCIN  
L16 52 S L14 AND L15  
L17 0 S L16 NOT L15  
L18 9 S LL16 NOT L14  
L19 230 S ACNE/TI  
L20 121 S L19 AND L2  
L21 5 S L20 AND L3  
L22 0 S L21 NOT L15  
L23 5 S L21 AND L15  
L24 1 S L23 AND RADICAL?

=> s skin/ti

L25 4183 SKIN/TI

=> s l25 and l2

L26 542 L25 AND L2

=> s l26 and l3

L27 3 L26 AND L3

=> s l27 and l15

L28 3 L27 AND L15

=> s tertiary amine?

128001 TERTIARY

253053 AMINE?

L29 60027 TERTIARY AMINE?  
(TERTIARY(W)AMINE?)

=> s l29 and l28

L30 0 L29 AND L28

=> s l25 and l29

L31 181 L25 AND L29

=> d his

(FILE 'HOME' ENTERED AT 10:41:50 ON 27 JUL 2003)

FILE 'USPATFULL' ENTERED AT 10:42:24 ON 27 JUL 2003

L1 7243 S ACNE?  
L2 118483 S PEROXIDE?  
L3 1027 S DAPSONE?  
L4 2062 S L1 AND L2  
L5 64 S L3 AND L4  
L6 25482 S BENZOYL PEROXIDE?  
L7 34 S L5 AND L6  
L8 41785 S FERROUS OR TRANSITIONAL METAL?  
L9 4 S L7 AND L8  
L10 2524243 S METHOD? OR PROCESS?  
L11 25097 S L10 AND L6  
L12 63 S L3 AND L11  
L13 9188 S ACNE OR SKIN CARE  
L14 63 S L11 AND L12  
L15 6527 S ERYTHROMYCIN  
L16 52 S L14 AND L15  
L17 0 S L16 NOT L15  
L18 9 S LL16 NOT L14  
L19 230 S ACNE/TI  
L20 121 S L19 AND L2  
L21 5 S L20 AND L3

10/091,607

L22 0 S L21 NOT L15  
L23 5 S L21 AND L15  
L24 1 S L23 AND RADICAL?  
L25 4183 S SKIN/TI  
L26 542 S L25 AND L2  
L27 3 S L26 AND L3  
L28 3 S L27 AND L15  
L29 60027 S TERTIARY AMINE?  
L30 0 S L29 AND L28  
L31 181 S L25 AND L29

=> s l31 and l2

L32 63 L31 AND L2

=> s l32 and l3

L33 0 L32 AND L3

=> s l32 and acne

6546 ACNE

L34 27 L32 AND ACNE

=> s l34 and iron?

275146 IRON?

L35 21 L34 AND IRON?

=> s l35 and radical?

206537 RADICAL?

L36 21 L35 AND RADICAL?

=> d his

(FILE 'HOME' ENTERED AT 10:41:50 ON 27 JUL 2003)

FILE 'USPATFULL' ENTERED AT 10:42:24 ON 27 JUL 2003

L1 7243 S ACNE?  
L2 118483 S PEROXIDE?  
L3 1027 S DAPSONE?  
L4 2062 S L1 AND L2  
L5 64 S L3 AND L4  
L6 25482 S BENZOYL PEROXIDE?  
L7 34 S L5 AND L6  
L8 41785 S FERROUS OR TRANSITIONAL METAL?  
L9 4 S L7 AND L8  
L10 2524243 S METHOD? OR PROCESS?  
L11 25097 S L10 AND L6  
L12 63 S L3 AND L11  
L13 9188 S ACNE OR SKIN CARE  
L14 63 S L11 AND L12  
L15 6527 S ERYTHROMYCIN  
L16 52 S L14 AND L15  
L17 0 S L16 NOT L15  
L18 9 S L16 NOT L14  
L19 230 S ACNE/TI  
L20 121 S L19 AND L2  
L21 5 S L20 AND L3  
L22 0 S L21 NOT L15  
L23 5 S L21 AND L15  
L24 1 S L23 AND RADICAL?  
L25 4183 S SKIN/TI  
L26 542 S L25 AND L2  
L27 3 S L26 AND L3  
L28 3 S L27 AND L15



10/091,607

L29 60027 S TERTIARY AMINE?  
L30 0 S L29 AND L28  
L31 181 S L25 AND L29  
L32 63 S L31 AND L2  
L33 0 S L32 AND L3  
L34 27 S L32 AND ACNE  
L35 21 S L34 AND IRON?  
L36 21 S L35 AND RADICAL?

=> s 136 and 16

L37 21 L36 AND L6

=> s 115 and 137

L38 21 L15 AND L37

=>

=> d 128 ibib abs 1-3

L28 ANSWER 1 OF 3 USPATFULL on STN

ACCESSION NUMBER: 90:5872 USPATFULL

TITLE: Pharmaceutical vehicles for enhancing penetration and retention in the **skin**

INVENTOR(S): Allen, Larry M., Denver, CO, United States

PATENT ASSIGNEE(S): Chemex Pharmaceuticals, Inc., Denver, CO, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4895727		19900123
APPLICATION INFO.:	US 1985-730682		19850503 (6)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Maple, John S.		
LEGAL REPRESENTATIVE:	Kenyon & Kenyon		
NUMBER OF CLAIMS:	30		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)		
LINE COUNT:	1116		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention is a method of inducing a reservoir effect in skin and mucous membranes so as to enhance penetration and retention and reduce transdermal flux of topically applied therapeutic and cosmetic pharmacologically active agents. The invention also relates to topical treatment methods involving such reservoir effect enhancers, and to pharmaceutical compositions containing them.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 2 OF 3 USPATFULL on STN

ACCESSION NUMBER: 89:97369 USPATFULL

TITLE: Topical transretinoids for treatment of acne and **skin** diseases

INVENTOR(S): Parish, Harlie A., Memphis, TN, United States

Purcell, William P., Memphis, TN, United States

PATENT ASSIGNEE(S): Molecular Design International, Memphis, TN, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4885311		19891205
APPLICATION INFO.:	US 1987-67536		19870629 (7)
DOCUMENT TYPE:	Utility		

10/091,607

FILE SEGMENT: Granted  
PRIMARY EXAMINER: Lone, Werren B.  
ASSISTANT EXAMINER: Clarke, Vera C.  
LEGAL REPRESENTATIVE: Waldron & Associates  
NUMBER OF CLAIMS: 14  
EXEMPLARY CLAIM: 1,3  
LINE COUNT: 405

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Esters and amides of 13-trans-retinoic acid are disclosed which are used for the treatment of acne and skin diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 3 OF 3 USPATFULL on STN

ACCESSION NUMBER: 87:47047 USPATFULL  
TITLE: Topical prodrugs for treatment of acne and skin diseases  
INVENTOR(S): Parish, Harlie A., Memphis, TN, United States  
Purcell, William P., Memphis, TN, United States  
PATENT ASSIGNEE(S): Molecular Design International, Memphis, TN, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4677120		19870630
APPLICATION INFO.:	US 1985-760881		19850731 (6)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Lone, Werren B.		
ASSISTANT EXAMINER:	Clarke, Vera C.		
LEGAL REPRESENTATIVE:	Waldron, James S.		
NUMBER OF CLAIMS:	14		
EXEMPLARY CLAIM:	1,3		
LINE COUNT:	623		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Esters and amides of 13-cis-retinoic acid are disclosed which are used for the treatment of acne and skin diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 10:41:50 ON 27 JUL 2003)

FILE 'USPATFULL' ENTERED AT 10:42:24 ON 27 JUL 2003

L1 7243 S ACNE?  
L2 118483 S PEROXIDE?  
L3 1027 S DAPSONE?  
L4 2062 S L1 AND L2  
L5 64 S L3 AND L4  
L6 25482 S BENZOYL PEROXIDE?  
L7 34 S L5 AND L6  
L8 41785 S FERROUS OR TRANSITIONAL METAL?  
L9 4 S L7 AND L8  
L10 2524243 S METHOD? OR PROCESS?  
L11 25097 S L10 AND L6  
L12 63 S L3 AND L11  
L13 9188 S ACNE OR SKIN CARE  
L14 63 S L11 AND L12  
L15 6527 S ERYTHROMYCIN  
L16 52 S L14 AND L15

10/091,607

L17 0 S L16 NOT L15  
L18 9 S LL16 NOT L14  
L19 230 S ACNE/TI  
L20 121 S L19 AND L2  
L21 5 S L20 AND L3  
L22 0 S L21 NOT L15  
L23 5 S L21 AND L15  
L24 1 S L23 AND RADICAL?  
L25 4183 S SKIN/TI  
L26 542 S L25 AND L2  
L27 3 S L26 AND L3  
L28 3 S L27 AND L15  
L29 60027 S TERTIARY AMINE?  
L30 0 S L29 AND L28  
L31 181 S L25 AND L29  
L32 63 S L31 AND L2  
L33 0 S L32 AND L3  
L34 27 S L32 AND ACNE  
L35 21 S L34 AND IRON?  
L36 21 S L35 AND RADICAL?  
L37 21 S L36 AND L6  
L38 21 S L15 AND L37

=> d 127 ibib abs 1-3

L27 ANSWER 1 OF 3 USPATFULL on STN

ACCESSION NUMBER: 90:5872 USPATFULL

TITLE: Pharmaceutical vehicles for enhancing penetration and retention in the **skin**

INVENTOR(S): Allen, Larry M., Denver, CO, United States

PATENT ASSIGNEE(S): Chemex Pharmaceuticals, Inc., Denver, CO, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4895727		19900123
APPLICATION INFO.:	US 1985-730682		19850503 (6)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Maple, John S.		
LEGAL REPRESENTATIVE:	Kenyon & Kenyon		
NUMBER OF CLAIMS:	30		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)		
LINE COUNT:	1116		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention is a method of inducing a reservoir effect in skin and mucous membranes so as to enhance penetration and retention and reduce transdermal flux of topically applied therapeutic and cosmetic pharmacologically active agents. The invention also relates to topical treatment methods involving such reservoir effect enhancers, and to pharmaceutical compositions containing them.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L27 ANSWER 2 OF 3 USPATFULL on STN

ACCESSION NUMBER: 89:97369 USPATFULL

TITLE: Topical transretinoids for treatment of acne and **skin** diseases

INVENTOR(S): Parish, Harlie A., Memphis, TN, United States

Purcell, William P., Memphis, TN, United States

PATENT ASSIGNEE(S): Molecular Design International, Memphis, TN, United

10/091,607

States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4885311		19891205
APPLICATION INFO.:	US 1987-67536		19870629 (7)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Lone, Werren B.		
ASSISTANT EXAMINER:	Clarke, Vera C.		
LEGAL REPRESENTATIVE:	Waldron & Associates		
NUMBER OF CLAIMS:	14		
EXEMPLARY CLAIM:	1,3		
LINE COUNT:	405		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Esters and amides of 13-trans-retinoic acid are disclosed which are used for the treatment of acne and skin diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L27 ANSWER 3 OF 3 USPATFULL on STN

ACCESSION NUMBER: 87:47047 USPATFULL

TITLE: Topical prodrugs for treatment of acne and skin diseases

INVENTOR(S): Parish, Harlie A., Memphis, TN, United States  
Purcell, William P., Memphis, TN, United States

PATENT ASSIGNEE(S): Molecular Design International, Memphis, TN, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4677120		19870630
APPLICATION INFO.:	US 1985-760881		19850731 (6)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Lone, Werren B.		
ASSISTANT EXAMINER:	Clarke, Vera C.		
LEGAL REPRESENTATIVE:	Waldron, James S.		
NUMBER OF CLAIMS:	14		
EXEMPLARY CLAIM:	1,3		
LINE COUNT:	623		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Esters and amides of 13-cis-retinoic acid are disclosed which are used for the treatment of acne and skin diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d 123 1-5 ibib abs

L23 ANSWER 1 OF 5 USPATFULL on STN

ACCESSION NUMBER: 2002:332478 USPATFULL

TITLE: Acne patch

INVENTOR(S): Buseman, Teri, Minnetonka, MN, United States  
Rolf, David, Eden Prairie, MN, United States  
McWhorter, Daniel M., Eagan, MN, United States

PATENT ASSIGNEE(S): Lec Tec Corporation, Minnetonka, MN, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6495158	B1	20021217

10/091,607

APPLICATION INFO.: US 2001-766885 20010119 (9)  
DOCUMENT TYPE: Utility  
FILE SEGMENT: GRANTED  
PRIMARY EXAMINER: Dees, Jos' G.  
ASSISTANT EXAMINER: Haghighatian, Mina  
LEGAL REPRESENTATIVE: Schwegman, Lundberg, Woessner & Kluth, P.A.  
NUMBER OF CLAIMS: 77  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 10 Drawing Figure(s); 5 Drawing Page(s)  
LINE COUNT: 1816

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An adhesive patch is provided wherein the patch includes a flexible backing having a front side and a back side. The patch also includes a therapeutic formulation positioned on and in at least a portion of the front side of the backing such that the therapeutic formulation is partially embedded in at least a portion of the front side of the backing. At least a portion of the backing is treated with a hydrophobic sizing agent such that the portion of the backing that is treated with the hydrophobic sizing agent has a surface energy of about 20 dynes/cm.sup.2 to about 65 dynes/cm.sup.2. The therapeutic formulation includes a topical acne drug, a solvent that dissolves the topical acne drug, and a pressure sensitive adhesive.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L23 ANSWER 2 OF 5 USPATFULL on STN

ACCESSION NUMBER: 97:118083 USPATFULL  
TITLE: Method for treating acne  
INVENTOR(S): Peck, Gary L., Silver Spring, MD, United States  
PATENT ASSIGNEE(S): The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5698593		19971216
APPLICATION INFO.:	US 1993-47007		19930415 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1991-735113, filed on 24 Jul 1991, now abandoned which is a continuation of Ser. No. US 1988-186260, filed on 26 Apr 1988, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Weddington, Kevin E.		
LEGAL REPRESENTATIVE:	Hyman, Laurence J. Office of Technology Transfer, NIH		
NUMBER OF CLAIMS:	11		
EXEMPLARY CLAIM:	1		
LINE COUNT:	393		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Nodulocystic and conglobate acne in humans can be alleviated by the oral administration of 13-cis-retinoic acid or a derivative thereof. The active ingredient is administered in a dosage of from about 1.5 to about 3 mg/kg of body weight per day for a period of from about two to about four weeks.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L23 ANSWER 3 OF 5 USPATFULL on STN

ACCESSION NUMBER: 96:70456 USPATFULL  
TITLE: Combination method of treating acne using 4-AZA-5.alpha.-cholestan-ones and 4-AZA-5.alpha.-androstan-ones as selective 5.alpha.-reductase inhibitors with anti-bacterial, keratolytic, or

10/091,607

INVENTOR(S): anti-inflammatory agents  
Waldstreicher, Joanne, Scotch Plains, NJ, United States  
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5543417		19960806
APPLICATION INFO.:	US 1994-327078		19941021 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Killos, Paul J.		
LEGAL REPRESENTATIVE:	Fitch, Catherine D., North, Robert J., Winokur, Melvin		
NUMBER OF CLAIMS:	31		
EXEMPLARY CLAIM:	1		
LINE COUNT:	3981		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Described is a combination method using selective inhibitors of  
5.alpha.-reductase 1 and/or 2 including 7.beta.-substituted  
4-aza-5.alpha.-cholestan-3-ones and related 4-aza-5.alpha.-androstan-3-  
one compounds which are useful in the treatment of acne vulgaris in  
combination with at least one agent selected from an antibacterial,  
keratolytic, and/or an anti-inflammatory.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L23 ANSWER 4 OF 5 USPATFULL on STN

ACCESSION NUMBER: 89:97369 USPATFULL  
TITLE: Topical transretinoids for treatment of acne  
and skin diseases  
INVENTOR(S): Parish, Harlie A., Memphis, TN, United States  
Purcell, William P., Memphis, TN, United States  
PATENT ASSIGNEE(S): Molecular Design International, Memphis, TN, United  
States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4885311		19891205
APPLICATION INFO.:	US 1987-67536		19870629 (7)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Lone, Werren B.		
ASSISTANT EXAMINER:	Clarke, Vera C.		
LEGAL REPRESENTATIVE:	Waldron & Associates		
NUMBER OF CLAIMS:	14		
EXEMPLARY CLAIM:	1,3		
LINE COUNT:	405		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Esters and amides of 13-trans-retinoic acid are disclosed which are used  
for the treatment of acne and skin diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L23 ANSWER 5 OF 5 USPATFULL on STN

ACCESSION NUMBER: 87:47047 USPATFULL  
TITLE: Topical prodrugs for treatment of acne and  
skin diseases  
INVENTOR(S): Parish, Harlie A., Memphis, TN, United States  
Purcell, William P., Memphis, TN, United States  
PATENT ASSIGNEE(S): Molecular Design International, Memphis, TN, United  
States (U.S. corporation)

10/091,607

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4677120		19870630
APPLICATION INFO.:	US 1985-760881		19850731 (6)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Lone, Werren B.		
ASSISTANT EXAMINER:	Clarke, Vera C.		
LEGAL REPRESENTATIVE:	Waldron, James S.		
NUMBER OF CLAIMS:	14		
EXEMPLARY CLAIM:	1,3		
LINE COUNT:	623		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Esters and amides of 13-cis-retinoic acid are disclosed which are used for the treatment of acne and skin diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s d his  
1465381 D  
270752 HIS  
L39 562 D HIS  
(D(W)HIS)

=> d his

(FILE 'HOME' ENTERED AT 10:41:50 ON 27 JUL 2003)

FILE 'USPATFULL' ENTERED AT 10:42:24 ON 27 JUL 2003

L1 7243 S ACNE?  
L2 118483 S PEROXIDE?  
L3 1027 S DAPSONE?  
L4 2062 S L1 AND L2  
L5 64 S L3 AND L4  
L6 25482 S BENZOYL PEROXIDE?  
L7 34 S L5 AND L6  
L8 41785 S FERROUS OR TRANSITIONAL METAL?  
L9 4 S L7 AND L8  
L10 2524243 S METHOD? OR PROCESS?  
L11 25097 S L10 AND L6  
L12 63 S L3 AND L11  
L13 9188 S ACNE OR SKIN CARE  
L14 63 S L11 AND L12  
L15 6527 S ERYTHROMYCIN  
L16 52 S L14 AND L15  
L17 0 S L16 NOT L15  
L18 9 S L16 NOT L14  
L19 230 S ACNE/TI  
L20 121 S L19 AND L2  
L21 5 S L20 AND L3  
L22 0 S L21 NOT L15  
L23 5 S L21 AND L15  
L24 1 S L23 AND RADICAL?  
L25 4183 S SKIN/TI  
L26 542 S L25 AND L2  
L27 3 S L26 AND L3  
L28 3 S L27 AND L15  
L29 60027 S TERTIARY AMINE?  
L30 0 S L29 AND L28  
L31 181 S L25 AND L29  
L32 63 S L31 AND L2

10/091,607

L33 0 S L32 AND L3  
L34 27 S L32 AND ACNE  
L35 21 S L34 AND IRON?  
L36 21 S L35 AND RADICAL?  
L37 21 S L36 AND L6  
L38 21 S L15 AND L37  
L39 562 S D HIS

=> s acne/ti or skin care/ti

230 ACNE/TI  
4183 SKIN/TI  
1843 CARE/TI  
248 SKIN CARE/TI  
((SKIN(W)CARE)/TI)

L40 478 ACNE/TI OR SKIN CARE/TI

=> d his

(FILE 'HOME' ENTERED AT 10:41:50 ON 27 JUL 2003)

FILE 'USPATFULL' ENTERED AT 10:42:24 ON 27 JUL 2003

L1 7243 S ACNE?  
L2 118483 S PEROXIDE?  
L3 1027 S DAPSONE?  
L4 2062 S L1 AND L2  
L5 64 S L3 AND L4  
L6 25482 S BENZOYL PEROXIDE?  
L7 34 S L5 AND L6  
L8 41785 S FERROUS OR TRANSITIONAL METAL?  
L9 4 S L7 AND L8  
L10 2524243 S METHOD? OR PROCESS?  
L11 25097 S L10 AND L6  
L12 63 S L3 AND L11  
L13 9188 S ACNE OR SKIN CARE  
L14 63 S L11 AND L12  
L15 6527 S ERYTHROMYCIN  
L16 52 S L14 AND L15  
L17 0 S L16 NOT L15  
L18 9 S L16 NOT L14  
L19 230 S ACNE/TI  
L20 121 S L19 AND L2  
L21 5 S L20 AND L3  
L22 0 S L21 NOT L15  
L23 5 S L21 AND L15  
L24 1 S L23 AND RADICAL?  
L25 4183 S SKIN/TI  
L26 542 S L25 AND L2  
L27 3 S L26 AND L3  
L28 3 S L27 AND L15  
L29 60027 S TERTIARY AMINE?  
L30 0 S L29 AND L28  
L31 181 S L25 AND L29  
L32 63 S L31 AND L2  
L33 0 S L32 AND L3  
L34 27 S L32 AND ACNE  
L35 21 S L34 AND IRON?  
L36 21 S L35 AND RADICAL?  
L37 21 S L36 AND L6  
L38 21 S L15 AND L37  
L39 562 S D HIS  
L40 478 S ACNE/TI OR SKIN CARE/TI



10/091,607

=> s 12 and 140  
L41 162 L2 AND L40

=> s 141 and 13  
L42 5 L41 AND L3

=> d 1-5 ibib abs

L42 ANSWER 1 OF 5 USPATFULL on STN

ACCESSION NUMBER: 2002:332478 USPATFULL

TITLE: Acne patch

INVENTOR(S): Buseman, Teri, Minnetonka, MN, United States  
Rolf, David, Eden Prairie, MN, United States  
McWhorter, Daniel M., Eagan, MN, United States

PATENT ASSIGNEE(S): Lec Tec Corporation, Minnetonka, MN, United States  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6495158	B1	20021217
APPLICATION INFO.:	US 2001-766885		20010119 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Dees, Jos' G.		
ASSISTANT EXAMINER:	Haghighatian, Mina		
LEGAL REPRESENTATIVE:	Schwegman, Lundberg, Woessner & Kluth, P.A.		
NUMBER OF CLAIMS:	77		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	10 Drawing Figure(s); 5 Drawing Page(s)		
LINE COUNT:	1816		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An adhesive patch is provided wherein the patch includes a flexible backing having a front side and a back side. The patch also includes a therapeutic formulation positioned on and in at least a portion of the front side of the backing such that the therapeutic formulation is partially embedded in at least a portion of the front side of the backing. At least a portion of the backing is treated with a hydrophobic sizing agent such that the portion of the backing that is treated with the hydrophobic sizing agent has a surface energy of about 20 dynes/cm.<sup>sup.2</sup> to about 65 dynes/cm.<sup>sup.2</sup>. The therapeutic formulation includes a topical acne drug, a solvent that dissolves the topical acne drug, and a pressure sensitive adhesive.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L42 ANSWER 2 OF 5 USPATFULL on STN

ACCESSION NUMBER: 97:118083 USPATFULL

TITLE: Method for treating **acne**

INVENTOR(S): Peck, Gary L., Silver Spring, MD, United States

PATENT ASSIGNEE(S): The United States of America as represented by the  
Department of Health and Human Services, Washington,  
DC, United States (U.S. government)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5698593		19971216
APPLICATION INFO.:	US 1993-47007		19930415 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1991-735113, filed on 24 Jul 1991, now abandoned which is a continuation of Ser. No. US 1988-186260, filed on 26 Apr 1988, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		

10/091,607

PRIMARY EXAMINER: Weddington, Kevin E.  
LEGAL REPRESENTATIVE: Hyman, Laurence J. Office of Technology Transfer, NIH  
NUMBER OF CLAIMS: 11  
EXEMPLARY CLAIM: 1  
LINE COUNT: 393

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Nodulocystic and conglobate acne in humans can be alleviated by the oral administration of 13-cis-retinoic acid or a derivative thereof. The active ingredient is administered in a dosage of from about 1.5 to about 3 mg/kg of body weight per day for a period of from about two to about four weeks.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L42 ANSWER 3 OF 5 USPATFULL on STN

ACCESSION NUMBER: 96:70456 USPATFULL

TITLE: Combination method of treating acne using 4-AZA-5.alpha.-cholestan-ones and 4-AZA-5.alpha.-androstan-ones as selective 5.alpha.-reductase inhibitors with anti-bacterial, keratolytic, or anti-inflammatory agents

INVENTOR(S): Waldstreicher, Joanne, Scotch Plains, NJ, United States

PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5543417		19960806
APPLICATION INFO.:	US 1994-327078		19941021 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Killos, Paul J.		
LEGAL REPRESENTATIVE:	Fitch, Catherine D., North, Robert J., Winokur, Melvin		
NUMBER OF CLAIMS:	31		
EXEMPLARY CLAIM:	1		
LINE COUNT:	3981		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Described is a combination method using selective inhibitors of 5.alpha.-reductase 1 and/or 2 including 7.beta.-substituted 4-aza-5.alpha.-cholestan-3-ones and related 4-aza-5.alpha.-androstan-3-one compounds which are useful in the treatment of acne vulgaris in combination with at least one agent selected from an antibacterial, keratolytic, and/or an anti-inflammatory.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L42 ANSWER 4 OF 5 USPATFULL on STN

ACCESSION NUMBER: 89:97369 USPATFULL

TITLE: Topical transretinoids for treatment of acne and skin diseases

INVENTOR(S): Parish, Harlie A., Memphis, TN, United States

Purcell, William P., Memphis, TN, United States

PATENT ASSIGNEE(S): Molecular Design International, Memphis, TN, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4885311		19891205
APPLICATION INFO.:	US 1987-67536		19870629 (7)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Lone, Werren B.		

10/091,607

ASSISTANT EXAMINER: Clarke, Vera C.  
LEGAL REPRESENTATIVE: Waldron & Associates  
NUMBER OF CLAIMS: 14  
EXEMPLARY CLAIM: 1,3  
LINE COUNT: 405

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Esters and amides of 13-trans-retinoic acid are disclosed which are used  
for the treatment of acne and skin diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L42 ANSWER 5 OF 5 USPATFULL on STN

ACCESSION NUMBER: 87:47047 USPATFULL

TITLE: Topical prodrugs for treatment of **acne** and  
skin diseases

INVENTOR(S): Parish, Harlie A., Memphis, TN, United States  
Purcell, William P., Memphis, TN, United States

PATENT ASSIGNEE(S): Molecular Design International, Memphis, TN, United  
States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4677120		19870630
APPLICATION INFO.:	US 1985-760881		19850731 (6)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Lone, Werren B.		
ASSISTANT EXAMINER:	Clarke, Vera C.		
LEGAL REPRESENTATIVE:	Waldron, James S.		
NUMBER OF CLAIMS:	14		
EXEMPLARY CLAIM:	1,3		
LINE COUNT:	623		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Esters and amides of 13-cis-retinoic acid are disclosed which are used  
for the treatment of acne and skin diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.